<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" id="jah310122" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Am Heart Assoc</journal-id><journal-id journal-id-type="iso-abbrev">J Am Heart Assoc</journal-id><journal-id journal-id-type="doi">10.1002/(ISSN)2047-9980</journal-id><journal-id journal-id-type="publisher-id">JAH3</journal-id><journal-id journal-id-type="hwp">ahaoa</journal-id><journal-title-group><journal-title>Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease</journal-title></journal-title-group><issn pub-type="epub">2047-9980</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">39344668</article-id><article-id pub-id-type="pmc">PMC11681471</article-id>
<article-id pub-id-type="doi">10.1161/JAHA.124.035011</article-id><article-id pub-id-type="publisher-id">JAH310122</article-id><article-id pub-id-type="other">JAHA/2024/035011</article-id><article-categories><subj-group subj-group-type="overline"><subject>Original Research</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Research</subject><subj-group subj-group-type="heading"><subject>Cardiovascular Surgery</subject></subj-group></subj-group></article-categories><title-group><article-title>Low Frequency Ventilation During Cardiopulmonary Bypass to Protect Postoperative Lung Function in Cardiac Valvular Surgery: The PROTECTION Phase <styled-content style="fixed-case" toggle="no">II</styled-content> Randomized Trial</article-title><alt-title alt-title-type="right-running-head">
<styled-content style="fixed-case" toggle="no">LFV</styled-content> During Cardiac Surgery for Lung Protection</alt-title><alt-title alt-title-type="left-running-head">Rogers et&#x000a0;al</alt-title></title-group><contrib-group><contrib id="jah310122-cr-0001" contrib-type="author"><name><surname>Rogers</surname><given-names>Chris A.</given-names></name><degrees>PhD</degrees><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-9624-2615</contrib-id><xref rid="jah310122-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="jah310122-cr-0002" contrib-type="author"><name><surname>Mazza</surname><given-names>Graziella</given-names></name><degrees>PhD</degrees><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-6986-1699</contrib-id><xref rid="jah310122-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="jah310122-cr-0003" contrib-type="author"><name><surname>Maishman</surname><given-names>Rachel</given-names></name><degrees>BSc, MSc</degrees><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-5052-5951</contrib-id><xref rid="jah310122-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="jah310122-cr-0004" contrib-type="author"><name><surname>Thirard</surname><given-names>Russell</given-names></name><degrees>BSc, MSc</degrees><xref rid="jah310122-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="jah310122-cr-0005" contrib-type="author"><name><surname>Evans</surname><given-names>Jonathan</given-names></name><degrees>BSc</degrees><xref rid="jah310122-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="jah310122-cr-0006" contrib-type="author"><name><surname>de Jesus</surname><given-names>Samantha</given-names></name><degrees>MPharm</degrees><xref rid="jah310122-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="jah310122-cr-0007" contrib-type="author"><name><surname>Beard</surname><given-names>Chloe</given-names></name><degrees>BSc</degrees><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-9802-4171</contrib-id><xref rid="jah310122-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="jah310122-cr-0008" contrib-type="author"><name><surname>Angelini</surname><given-names>Gianni</given-names></name><degrees>MD, ChM</degrees><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-1753-3730</contrib-id><xref rid="jah310122-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="jah310122-cr-0009" contrib-type="author"><name><surname>Millar</surname><given-names>Ann</given-names></name><degrees>MD, FRCP</degrees><xref rid="jah310122-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="jah310122-cr-0010" contrib-type="author"><name><surname>Jarad</surname><given-names>Nabil</given-names></name><degrees>PhD, FRCP</degrees><xref rid="jah310122-aff-0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib id="jah310122-cr-0011" contrib-type="author"><name><surname>Tomkins</surname><given-names>Sally</given-names></name><degrees>MB&#x02010;Bchir</degrees><xref rid="jah310122-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="jah310122-cr-0012" contrib-type="author"><name><surname>Hillier</surname><given-names>James</given-names></name><degrees>MA, MBBS</degrees><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-9591-6510</contrib-id><xref rid="jah310122-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="jah310122-cr-0013" contrib-type="author"><name><surname>Suleiman</surname><given-names>M&#x02010;Saadeh</given-names></name><degrees>PhD</degrees><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-6080-480X</contrib-id><xref rid="jah310122-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="jah310122-cr-0014" contrib-type="author" corresp="yes"><name><surname>Ascione</surname><given-names>Raimondo</given-names></name><degrees>MD, ChM</degrees><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-8045-5619</contrib-id><xref rid="jah310122-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><address><email>r.ascione@bristol.ac.uk</email></address></contrib></contrib-group><aff id="jah310122-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">Bristol Trials Centre, Bristol Medical School</named-content>
<institution>University of Bristol</institution>
<country country="GB">UK</country>
</aff><aff id="jah310122-aff-0002">
<label>
<sup>2</sup>
</label>
<named-content content-type="organisation-division">Faculty of Life and Health Sciences, Bristol Heart Institute</named-content>
<institution>University of Bristol</institution>
<country country="GB">UK</country>
</aff><aff id="jah310122-aff-0003">
<label>
<sup>3</sup>
</label>
<named-content content-type="organisation-division">Respiratory Medicine</named-content>
<institution>Southmead Hospital Bristol</institution>
<country country="GB">UK</country>
</aff><aff id="jah310122-aff-0004">
<label>
<sup>4</sup>
</label>
<named-content content-type="organisation-division">Department of Respiratory Medicine</named-content>
<institution>University Hospital Bristol and Weston NHS Foundation Trust</institution>
<city>Bristol</city>
<country country="GB">UK</country>
</aff><author-notes><corresp id="correspondenceTo">
<label>*</label>
Correspondence to: Raimondo Ascione, Faculty of Life and Health Sciences, Bristol Heart Institute, University of Bristol, Zone A, Level 7, Bristol Royal Infirmary, Bristol BS2 8HW, UK. Email: <email>r.ascione@bristol.ac.uk</email>
<break/>
</corresp></author-notes><pub-date pub-type="epub"><day>30</day><month>9</month><year>2024</year></pub-date><pub-date pub-type="collection"><day>01</day><month>10</month><year>2024</year></pub-date><volume>13</volume><issue seq="20">19</issue><issue-id pub-id-type="doi">10.1002/jah3.v13.19</issue-id><elocation-id>e035011</elocation-id><history>
<date date-type="received"><day>14</day><month>2</month><year>2024</year></date>
<date date-type="accepted"><day>15</day><month>8</month><year>2024</year></date>
</history><permissions><!--Copyright &#x000a9; 2024 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell--><copyright-statement content-type="article-copyright">&#x000a9; 2024 The Author(s). Published on behalf of the American Heart Association, Inc., by Wiley.</copyright-statement><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="file:JAH3-13-e035011.pdf"/><abstract><sec id="jah310122-sec-0001"><title>Background</title><p>Cardiac surgery with cardiopulmonary bypass (CPB) triggers pulmonary injury. In this trial we assessed the feasibility, safety, and efficacy of low frequency ventilation (LFV) during CPB in patients undergoing valvular surgery.</p></sec><sec id="jah310122-sec-0002"><title>Methods and Results</title><p>Patients with severe mitral or aortic valve disease were randomized to either LFV or usual care. Primary outcomes included release of generic inflammatory and vascular biomarkers and the lung&#x02010;specific biomarker sRAGE (soluble receptor for advance glycation end products) up to 24 hours postsurgery. Secondary outcomes included pulmonary function tests and 6&#x02010;minute walking test up to 8&#x02009;weeks postdischarge. Sixty&#x02010;three patients were randomized (33 LFV versus 30 usual care). Mean age was 66.8&#x02009;years and 30% were female. LFV was associated with changes of sRAGE (soluble receptor for advance glycation end products) levels (geometric mean ratio, 3.05; [95% CI, 1.13&#x02013;8.24] 10&#x02009;minutes post CPB, and 1.07 [95% CI, 0.64&#x02013;1.79], 0.84 [95% CI, 0.55&#x02013;1.27], 0.67 [95% CI, 0.42&#x02013;1.07], and 0.62 [95% CI, 0.45&#x02013;0.85] at 2, 6, 12, and 24&#x02009;hours post CPB respectively). No changes were observed for any of the generic biomarkers. Respiratory index soon after surgery (mean difference, &#x02212;0.61 [95% CI, &#x02212;1.24 to 0.015] 10&#x02009;minutes post end of CPB), forced expiratory volume after 1&#x02009;second/forced vital capacity ratio (0.050 [95% CI, 0.007&#x02013;0.093] at 6 to 8&#x02009;weeks pos&#x02010;surgery), Forced vital capacity alone (95% CI, &#x02212;0.191&#x02009;L [&#x02212;0.394 to 0.012]) and 6&#x02010;minute walking test score at discharge (63.2&#x02009;m [95% CI, 12.9&#x02013;113.6]) were better preserved in the LFV group. No other differences were noted.</p></sec><sec id="jah310122-sec-0003"><title>Conclusions</title><p>The use of LFV during CPB in patients undergoing valvular surgery was feasible and safe and was associated with changes in sRAGE levels along with better preserved lung function and walking performance. These observations warrant further investigation in larger future studies.</p></sec><sec id="jah310122-sec-0004"><title>Registration</title><p>URL: <ext-link xlink:href="http://www.isrctn.com" ext-link-type="uri">https://www.isrctn.com</ext-link>; Unique Identifier: ISRCTN75795633.</p></sec></abstract><kwd-group kwd-group-type="author-generated"><kwd id="jah310122-kwd-0001">cardiopulmonary bypass</kwd><kwd id="jah310122-kwd-0002">low frequency ventilation</kwd><kwd id="jah310122-kwd-0003">lung protection</kwd><kwd id="jah310122-kwd-0004">pulmonary function tests</kwd><kwd id="jah310122-kwd-0005">sRAGE</kwd><kwd id="jah310122-kwd-0006">valvular surgery</kwd></kwd-group><kwd-group kwd-group-type="subject-categories"><title>Subject Categories</title><kwd>Cardiovascular Surgery</kwd><kwd>Treatment</kwd></kwd-group><counts><fig-count count="2"/><table-count count="3"/><page-count count="13"/><word-count count="7700"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>01 October 2024</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.5.0 mode:remove_FC converted:05.11.2024</meta-value></custom-meta></custom-meta-group></article-meta><notes><fn-group id="jah310122-ntgp-0001"><fn id="jah310122-note-0001"><p>This article was sent to John S. Ikonomidis, MD, PhD, Guest Editor, for review by expert referees, editorial decision, and final disposition.</p></fn><fn id="jah310122-note-0002"><p>Supplemental Material is available at <ext-link xlink:href="https://www.ahajournals.org/doi/suppl/10.1161/JAHA.124.035011" ext-link-type="uri">https://www.ahajournals.org/doi/suppl/10.1161/JAHA.124.035011</ext-link>
</p></fn><fn id="jah310122-note-0003"><p>For Sources of Funding and Disclosures, see page 12.</p></fn></fn-group></notes></front><body id="jah310122-body-0001"><def-list list-content="abbreviations" id="jah310122-dl-0001"><title>Nonstandard Abbreviations and Acronyms</title><def-item><term id="jah310122-li-0001">6MWT</term><def id="jah310122-li-0002"><p>6&#x02010;minute walking test</p></def></def-item><def-item><term id="jah310122-li-0003">CPB</term><def id="jah310122-li-0004"><p>cardiopulmonary bypass</p></def></def-item><def-item><term id="jah310122-li-0005">LFV</term><def id="jah310122-li-0006"><p>low frequency ventilation</p></def></def-item><def-item><term id="jah310122-li-0007">MV</term><def id="jah310122-li-0008"><p>mitral valve</p></def></def-item><def-item><term id="jah310122-li-0009">sRAGE</term><def id="jah310122-li-0010"><p>soluble receptor for advance glycation end products</p></def></def-item><def-item><term id="jah310122-li-0011">UC</term><def id="jah310122-li-0012"><p>usual care</p></def></def-item></def-list><p>
<boxed-text position="anchor" content-type="box" id="jah310122-blkfxd-0001"><caption><title>Clinical Perspective</title></caption><sec id="jah310122-sec-0007"><title>What Is New?</title><p>
<list list-type="bullet" id="jah310122-list-0001"><list-item id="jah310122-li-0013"><p>This study suggests that the use of low frequency ventilation during cardiopulmonary bypass in the targeted valvular population is feasible and safe.</p></list-item><list-item id="jah310122-li-0014"><p>In addition, it suggests that low frequency ventilation is associated with marked postoperative changes in circulating levels of the lung&#x02010;specific mediator sRage (soluble receptor for advance glycation end products), better preservation of lung function up to 8&#x02009;weeks after surgery, and improved walking performance at hospital discharge.</p></list-item></list>
</p></sec><sec id="jah310122-sec-0008"><title>What Are the Clinical Implications?</title><p>
<list list-type="bullet" id="jah310122-list-0002"><list-item id="jah310122-li-0015"><p>A future large phase III clinical trial powered on strong clinical primary outcomes and confirming the clinical efficacy of the proposed method could trigger future adoption of low frequency ventilation in routine clinical practice. In addition, if future mechanistic studies identify sRAGE as a key mediator during cardiopulmonary bypass&#x02010;related lung ischemia&#x02013;reperfusion injury, this might lead to the development of new drug&#x02010;based treatments.</p></list-item></list>
</p></sec></boxed-text>
</p><p>Pulmonary injury during cardiac surgery with cardiopulmonary bypass (CPB) is still common.<xref rid="jah310122-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref>, <xref rid="jah310122-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref>, <xref rid="jah310122-bib-0003" ref-type="bibr">
<sup>3</sup>
</xref>, <xref rid="jah310122-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref>, <xref rid="jah310122-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref> Predisposing factors include general anesthesia, median sternotomy, prolonged CPB,<xref rid="jah310122-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref>, <xref rid="jah310122-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref>, <xref rid="jah310122-bib-0003" ref-type="bibr">
<sup>3</sup>
</xref>, <xref rid="jah310122-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref>, <xref rid="jah310122-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref> intraoperative lung collapse,<xref rid="jah310122-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref> inflammatory activation,<xref rid="jah310122-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref>, <xref rid="jah310122-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref>, <xref rid="jah310122-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref>, <xref rid="jah310122-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref> and perioperative blood transfusion.<xref rid="jah310122-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref>, <xref rid="jah310122-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref> To reduce postoperative lung injury, several methods of open&#x02010;lung ventilation during CPB have been tested over the years with conflicting results.<xref rid="jah310122-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref>, <xref rid="jah310122-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref>, <xref rid="jah310122-bib-0015" ref-type="bibr">
<sup>15</sup>
</xref>, <xref rid="jah310122-bib-0016" ref-type="bibr">
<sup>16</sup>
</xref>, <xref rid="jah310122-bib-0017" ref-type="bibr">
<sup>17</sup>
</xref>, <xref rid="jah310122-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref>, <xref rid="jah310122-bib-0019" ref-type="bibr">
<sup>19</sup>
</xref>, <xref rid="jah310122-bib-0020" ref-type="bibr">
<sup>20</sup>
</xref> A previous phase II trial in a mixed group of 62 patients undergoing coronary and valvular surgery<xref rid="jah310122-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref> and preclinical studies by our group in large animal<xref rid="jah310122-bib-0015" ref-type="bibr">s<sup>14,15</sup>
</xref> suggested that open&#x02010;lung methods during CPB might reduce inflammatory activation. However, a small phase II trial in patients undergoing only coronary artery bypass grafting (CABG) by our group suggested that the use of low frequency ventilation (LFV) during CPB did not reduce inflammatory activation and did not preserve perioperative lung function.<xref rid="jah310122-bib-0016" ref-type="bibr">
<sup>16</sup>
</xref> Recent larger trials have tested several open&#x02010;lung methods during cardiac surgery in different mixed surgical populations showing no benefits in predefined outcome measures.<xref rid="jah310122-bib-0017" ref-type="bibr">
<sup>17</sup>
</xref>, <xref rid="jah310122-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref>, <xref rid="jah310122-bib-0019" ref-type="bibr">
<sup>19</sup>
</xref>, <xref rid="jah310122-bib-0020" ref-type="bibr">
<sup>20</sup>
</xref>, <xref rid="jah310122-bib-0021" ref-type="bibr">
<sup>21</sup>
</xref> However, there is little in the literature on testing open&#x02010;lung treatments during CPB in selected patients with severe mitral or aortic valve disease undergoing open cardiac valvular surgery. Of note, previous studies assessing new open&#x02010;lung treatments during cardiac surgery in small phase I and II trials have focused on generic biomarkers rather than lung&#x02010;specific biomarkers.<xref rid="jah310122-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref>, <xref rid="jah310122-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref>, <xref rid="jah310122-bib-0015" ref-type="bibr">
<sup>15</sup>
</xref>, <xref rid="jah310122-bib-0016" ref-type="bibr">
<sup>16</sup>
</xref>, <xref rid="jah310122-bib-0017" ref-type="bibr">
<sup>17</sup>
</xref>, <xref rid="jah310122-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref>, <xref rid="jah310122-bib-0019" ref-type="bibr">
<sup>19</sup>
</xref>, <xref rid="jah310122-bib-0020" ref-type="bibr">
<sup>20</sup>
</xref>, <xref rid="jah310122-bib-0021" ref-type="bibr">
<sup>21</sup>
</xref> The sRAGE (soluble receptor for advance glycation end) product is a well&#x02010;established biomarker of lung&#x02010;specific injury that is used regularly in respiratory medicine, with changes in sRAGE circulating levels being associated with a variety of pulmonary conditions.<xref rid="jah310122-bib-0022" ref-type="bibr">
<sup>22</sup>
</xref>, <xref rid="jah310122-bib-0023" ref-type="bibr">
<sup>23</sup>
</xref>, <xref rid="jah310122-bib-0024" ref-type="bibr">
<sup>24</sup>
</xref>, <xref rid="jah310122-bib-0025" ref-type="bibr">
<sup>25</sup>
</xref>, <xref rid="jah310122-bib-0026" ref-type="bibr">
<sup>26</sup>
</xref>, <xref rid="jah310122-bib-0027" ref-type="bibr">
<sup>27</sup>
</xref> The aim of this phase II randomized controlled trial was to assess the feasibility, safety, and functional efficacy of LFV during CPB in selected patients with severe mitral or aortic valve disease undergoing open cardiac valvular surgery.</p><sec sec-type="methods" id="jah310122-sec-0009"><title>Methods</title><sec id="jah310122-sec-0010"><title>Study Design and Data Availability</title><p>A single&#x02010;center parallel&#x02010;group randomized controlled phase II trial. Participants were allocated in a 1:1 ratio to receive LFV during CPB or usual care (UC). Study participants were followed up for 6 to 8&#x02009;weeks after discharge. The trial was registered (ISRCTN75795633). The full study protocol is available at the Bristol Trials Centre, Bristol, UK, a UKCRC registered clinical trials unit.</p><p>The data underlying this article are available in this article and its supplementary online files. The raw data underlying the reported findings will be shared on reasonable request to the corresponding author.</p></sec><sec id="jah310122-sec-0011"><title>Target Population</title><p>Elective or urgent patients with severe mitral valve (MV) or aortic valve disease, 18&#x02009;years of age or older, who had been referred for valve repair or replacement surgery were selected for this study. In all cases, surgery was to be undertaken under general anesthesia via median sternotomy, CPB, and aortic cross&#x02010;clamping. Patients with left ventricular ejection fraction &#x0003e;25%, severe MV, or aortic valve stenosis or regurgitation were included. To minimize bias and confounding exclusion criteria included CABG alone, redo surgery, aortic surgery, pulmonary embolism requiring anticoagulation &#x0003e;3&#x02009;months, heart failure (New York Heart Association class IV), cardiogenic shock, chronic renal failure requiring dialysis, corticosteroid or immunosuppressive treatments, emergency/salvage operation, sepsis, or acute endocarditis. The diagnosis of severe MV or aortic valve stenosis or regurgitation was made by independent senior cardiologists based on standardized protocols and established echocardiographic guidelines. The decision to go for open surgical treatment was made via the Heart Team. The decision to exclude patients who had CABG alone was made by the Trial Steering Committee before starting patient recruitment based on the results of a small pilot study indicating no benefit of LVF in patients who had CABG alone.</p></sec><sec id="jah310122-sec-0012"><title>Study Settings</title><p>The study was conducted at the Bristol Heart Institute, a regional cardiac surgery center in the United Kingdom, according to the principles outlined in the Declaration of Helsinki. The University Hospital Bristol and Weston NHS Foundation Trust sponsored the trial. The Southmead Research Ethics Committee gave ethical approval including subsequent design amendments (Ref. CS/2009/3259) and all recruited patients gave informed consent. The trial, data collection, and data analysis were managed independently by the registered Bristol Clinical Trial Evaluation Unit (now Bristol Trials Centre&#x02014;BTC, Bristol, UK).</p></sec><sec id="jah310122-sec-0013"><title>Anesthesia, Mechanical Ventilation, and Open&#x02010;Lung Interventions During CPB</title><p>Consented patients were randomized to receive either LFV or usual care during CPB. Anesthesia, mechanical ventilation, CPB, surgical methods, and postoperative management were based on standardized protocols<xref rid="jah310122-bib-0028" ref-type="bibr">
<sup>28</sup>
</xref> with more details provided in Data&#x000a0;<xref rid="jah310122-supitem-0001" ref-type="supplementary-material">S1</xref>. Briefly, following a premedication, anesthesia was induced with a combination of midazolam, propofol, and fentanyl 5&#x02010;10&#x02009;mcg/kg, and muscle relaxation was achieved with vecuronium or rocuronium. Anesthesia was maintained with a combination of volatile anesthetic agent, propofol (2&#x02013;6&#x02009;mg/kg&#x02009;h) and fentanyl (5&#x02009;mcg/kg up to maximum of 20&#x02009;mcg/kg). Mechanical ventilation was the same in both groups and guided by routine clinical practice entailing a positive end&#x02010;expiratory pressure (PEEP) of 5&#x02009;cmH<sub>2</sub>O and normal volume control ventilation at the following settings: tidal volume of 6 to 8&#x02009;mL/kg, inspiratory/expiratory ratio of 1:2, FiO<sub>2</sub> of 100% for 5&#x02009;minutes to be reduced to 50% thereafter, and ventilation rate of 12/min aiming to obtain a favorable PaCO<sub>2</sub> (35.0&#x02013;45.0&#x02009;mm&#x02009;Hg) and pH (7.35&#x02013;7.45).</p><sec id="jah310122-sec-0014"><title>Low Frequency Ventilation</title><p>Once patients were on CPB, the ventilation was set up at a respiratory rate of 5&#x02009;inflations/min with air (21% oxygen) at a tidal volume of 6 to 8&#x02009;mL/kg and PEEP of 5&#x02009;cmH<sub>2</sub>O according to a standardized protocol. Just before weaning CPB a standardized lung recruitment maneuver was performed by increasing peak inspiratory pressure to 40&#x02009;cmH<sub>2</sub>O for 15&#x02009;seconds. Next, the ventilation was kept at strict pre&#x02010;CPB settings until the patients met the criteria for extubation.</p></sec><sec id="jah310122-sec-0015"><title>Usual Care</title><p>Once patients were on CPB, the lungs were disconnected from the ventilator and left collapsed for the entire CPB duration. Just before CPB weaning, the same lung recruitment maneuver described in the LVF group was performed by increasing peak inspiratory pressure to 40&#x02009;cmH<sub>2</sub>O for 15&#x02009;seconds. Then, the ventilation was kept at routine pre&#x02010;CPB settings, until the patients met the criteria for extubation.</p></sec></sec><sec id="jah310122-sec-0016"><title>Outcome Measures</title><sec id="jah310122-sec-0017"><title>Primary Biochemical Outcomes</title><p>The primary outcomes included the following generic biomarkers: TNF&#x003b1; (tumor necrosis factor alpha); IL1&#x003b2;, IL&#x02010;6, IL&#x02010;10 (interleukin&#x02010;1beta, 6, and 10), TXA2 (thromboxane A2); sICAM&#x02010;1 (soluble intercellular adhesion molecule&#x02010;1); sVCAM&#x02010;1 (soluble vascular adhesion molecule&#x02010;1); tPAI&#x02010;1 (tissue plasminogen activator inhibitor&#x02010;1); sphingosine 1&#x02010;phosphate<xref rid="jah310122-bib-0029" ref-type="bibr">
<sup>29</sup>
</xref>, <xref rid="jah310122-bib-0030" ref-type="bibr">
<sup>30</sup>
</xref>, <xref rid="jah310122-bib-0031" ref-type="bibr">
<sup>31</sup>
</xref>; and 1 lung&#x02010;specific biomarker (sRAGE) used regularly in respiratory medicine.<xref rid="jah310122-bib-0022" ref-type="bibr">
<sup>22</sup>
</xref>, <xref rid="jah310122-bib-0023" ref-type="bibr">
<sup>23</sup>
</xref>, <xref rid="jah310122-bib-0024" ref-type="bibr">
<sup>24</sup>
</xref>, <xref rid="jah310122-bib-0025" ref-type="bibr">
<sup>25</sup>
</xref>, <xref rid="jah310122-bib-0026" ref-type="bibr">
<sup>26</sup>
</xref>, <xref rid="jah310122-bib-0027" ref-type="bibr">
<sup>27</sup>
</xref> All biomarkers were measured serially in blood samples taken at baseline (postinduction of anesthesia), 10&#x02009;minutes and 2, 6, 12, and 24&#x02009;hours after CPB weaning.</p></sec><sec id="jah310122-sec-0018"><title>Secondary Functional Outcomes</title><p>These included sensitive pulmonary function tests routinely used in clinical practice:
<list list-type="order" id="jah310122-list-0003"><list-item id="jah310122-li-0016"><p>
<italic toggle="yes">Pulmonary function tests</italic>: Forced vital capacity (FVC), forced expiratory volume after 1&#x02009;second (FEV1) and FEV1/FVC ratio measured before surgery, at predischarge, and at 6 to 8&#x02009;weeks postsurgery.</p></list-item><list-item id="jah310122-li-0017"><p>
<italic toggle="yes">Pulmonary oxygen exchange</italic>: Alveolar&#x02010;arterial oxygenation gradients (PAO<sub>2</sub>&#x02013;PaO<sub>2</sub>) and respiratory index [(PAO<sub>2</sub>&#x02013;PaO<sub>2</sub>)/(PaO<sub>2</sub>)] measured at postinduction, 10&#x02009;minutes, 2, 4, and 12 hours after CPB weaning derived from serial hemogas analysis. Increase of alveolar&#x02010;arterial oxygenation gradient and of respiratory index indicate greater hypoxemia due to impaired oxygen exchange.</p></list-item><list-item id="jah310122-li-0018"><p>
<italic toggle="yes">Lung static and dynamic compliance</italic>: Peak airway pressure (cmH<sub>2</sub>O) measured at 2 and 4 hours after CPB weaning.</p></list-item><list-item id="jah310122-li-0019"><p>
<italic toggle="yes">Trapping of white blood cells</italic>: Left atrial/right atrial (LA/RA) white blood cell ratio measured before institution of CPB and at CPB weaning. A left atrial/right atrial white blood cell ratio &#x0003c;1 indicates trapping of leukocytes and platelets in the lungs.</p></list-item><list-item id="jah310122-li-0020"><p>
<italic toggle="yes">Functional exercise capacity</italic>: All patients were subjected to a 6&#x02010;minute walking test (6MWT) at predischarge. The 6MWT is a commonly used test for the objective assessment of functional exercise capacity in patients with moderate&#x02010;to&#x02010;severe pulmonary disease.<xref rid="jah310122-bib-0032" ref-type="bibr">
<sup>32</sup>
</xref>, <xref rid="jah310122-bib-0033" ref-type="bibr">
<sup>33</sup>
</xref>
</p></list-item></list>
</p></sec></sec><sec id="jah310122-sec-0019"><title>Clinical Outcome</title><p>Generic clinical outcome included bacteriologically proven chest infection, mechanical ventilation &#x0003e;24&#x02009;hours, postoperative need for continuous positive airway pressure, reintubation, tracheostomy, or acute respiratory distress syndrome up to 8&#x02009;weeks after surgery. In addition, a generic time until fit for discharge was calculated based on the time point when the patients had achieved predefined targets including being afebrile, heart and respiratory rates within normal range, saturation &#x02265;96% on room air, normal bowel function, and being physically mobile.</p></sec><sec id="jah310122-sec-0020"><title>Randomization and Blinding</title><p>Randomization sequence was according to a computer&#x02010;generated list drawn up by an independent operator before the start of the trial. Cohort minimization was used to achieve balanced distribution between groups of surgical procedure and poor baseline lung function (FEV1 &#x0003c;60% predicted). Allocations were concealed until a participant was recruited and registered onto a secure purpose&#x02010;designed electronic database. Randomization took place the evening before surgery; if a participant's surgery was unexpectedly rescheduled, they retained their randomized allocation. Data were collected anonymously on the electronic platform and each patient was assigned a unique identification number. Participants, hospital staff not involved in the surgery, and research personnel responsible for data collection and laboratory analyses were blinded to the treatment allocation.</p></sec><sec id="jah310122-sec-0021"><title>Statistical Analysis</title><p>All biomarkers were measured longitudinally over 6 consecutive time points to allow detection of a large effect in a small phase II trial.<xref rid="jah310122-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref>, <xref rid="jah310122-bib-0026" ref-type="bibr">
<sup>26</sup>
</xref> A sample size of 60 participants was chosen to provide 90% power to detect a difference in biomarkers of 0.60 SDs at the 5% significance (2 tailed), assuming a correlation of 0.5 between pre and postintervention measures and a correlation of 0.7 between repeated postintervention measures. All biomarkers were measured in duplicates, both included in the statistical analysis. Analyses were performed only for predefined primary biochemical and secondary functional outcomes on an intention&#x02010;to&#x02010;treat basis in line with a prespecified analysis plan. Outcomes were compared using regression methods. Models included treatment allocation, stratification variables, and baseline measures (where available) fitted as fixed effects. Longitudinal outcome models also included time (category variable) and treatment by time as fixed effects and participant and time fitted as random effects. If the interaction between treatment group and time was statistically significant at <italic toggle="yes">P</italic>&#x0003c;0.1, results are presented for each time point separately, otherwise the treatment by time interaction was removed from the model and an overall treatment effect is given. Alternative variance/covariance structures were compared (using likelihood ratio tests) to best allow for the correlation between measurements taken at different times for the same participant. Likelihood ratio tests were used to determine statistical significance, and 2&#x02010;tailed <italic toggle="yes">P</italic> values &#x0003c;0.05 were considered statistically significant. Results are reported as effect sizes with 95% CIs. Analyses were performed in Stata version 16.1 (Stata Corp LP, College Station, TX) or SAS version 9.4 (SAS Institute Inc, Cary, NC). Additional information on the statistical analysis is provided in Data&#x02009;<xref rid="jah310122-supitem-0001" ref-type="supplementary-material">S1</xref>.</p></sec></sec><sec sec-type="results" id="jah310122-sec-0022"><title>Results</title><p>This phase II trial is reported according to the Consolidated Standards of Reporting Trials guidelines. The flow chart is shown in Figure&#x000a0;<xref rid="jah310122-fig-0001" ref-type="fig">1</xref>.</p><fig position="float" fig-type="Figure" id="jah310122-fig-0001"><label>Figure 1</label><caption><title>CONSORT flow chart.</title><p>CONSORT flow chart illustrating the allocation of patients between groups, exclusions, withdrawals overtime and follow&#x02010;up. CONSORT indicates Consolidated Standards of Reporting Trials; and CPB, cardiopulmonary bypass.</p></caption><graphic xlink:href="JAH3-13-e035011-g001" position="anchor" id="jats-graphic-1"/></fig><sec id="jah310122-sec-0023"><title>Patient Recruitment and Timing of Data Collection/Validation, Laboratory Assays, and Data Analysis</title><p>Between January 5, 2011 and July 16, 2012, 65 eligible patients were recruited and randomized, 33 to LFV and 32 to UC. Participants were followed up 6 to 8&#x02009;weeks after surgery.</p><p>Two participants randomized to UC were withdrawn at surgery in line with study protocol due to intraoperative findings indicating additional procedures needed. One participant in the LVF group withdrew after discharge (Table&#x000a0;<xref rid="jah310122-supitem-0001" ref-type="supplementary-material">S1</xref>). All patients in the treatment group received LVF according to the predefined protocol. On completion of patient recruitment, clinical data collection and subsequent validation and database locking were completed by 2015. All biomarker laboratory assays were undertaken in duplicate with data validation completed by late 2015. All molecular and functional data were analyzed from mid&#x02010;2018 to mid&#x02010;2019 due to a gap in funding. Article preparation and its final approval by the Trial Unit lead was markedly delayed by the pandemic outbreak.</p></sec><sec id="jah310122-sec-0024"><title>Baseline Characteristics and Operative Data</title><p>Baseline characteristics, type of valvular disease, operative details, and preoperative medications are shown in Tables&#x000a0;<xref rid="jah310122-tbl-0001" ref-type="table">1</xref> and <xref rid="jah310122-tbl-0002" ref-type="table">2</xref> and Tables&#x000a0;<xref rid="jah310122-supitem-0001" ref-type="supplementary-material">S2</xref> and <xref rid="jah310122-supitem-0001" ref-type="supplementary-material">S3</xref>. The mean age was 66.8&#x02009;years (SD 10.7), with 19/63 (30.2%) of patients being female. Of the 63 patients 28 were in New York Heart Association Class III and 12 had left ventricular ejection fraction &#x02264;50%. All 63 patients were diagnosed with severe aortic or mitral valve stenosis or regurgitation based on baseline echocardiographic findings. Severe aortic or mitral valve stenosis or severe regurgitation were equally distributed among groups (Table&#x000a0;<xref rid="jah310122-tbl-0001" ref-type="table">1</xref>).</p><table-wrap position="float" id="jah310122-tbl-0001" content-type="Table"><label>Table 1</label><caption><p>Baseline Characteristics</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="2" colspan="1"/><th align="left" colspan="2" rowspan="1">Randomized to LFV (n=33)</th><th align="left" colspan="2" rowspan="1">Randomized to usual care (n=30)</th><th align="left" colspan="2" rowspan="1">Overall (n=63)</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1">n</th><th align="left" rowspan="1" colspan="1">%</th><th align="left" rowspan="1" colspan="1">n</th><th align="left" rowspan="1" colspan="1">%</th><th align="left" rowspan="1" colspan="1">n</th><th align="left" rowspan="1" colspan="1">%</th></tr></thead><tbody><tr><td align="left" colspan="7" rowspan="1">Baseline characteristics</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Age, y (SD)</td><td align="left" rowspan="1" colspan="1">64.9</td><td align="left" rowspan="1" colspan="1">10.0</td><td align="left" rowspan="1" colspan="1">68.9</td><td align="left" rowspan="1" colspan="1">11.1</td><td align="left" rowspan="1" colspan="1">66.8</td><td align="left" rowspan="1" colspan="1">10.7</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Female sex</td><td align="left" rowspan="1" colspan="1">6/33</td><td align="left" rowspan="1" colspan="1">18.2%</td><td align="left" rowspan="1" colspan="1">13/30</td><td align="left" rowspan="1" colspan="1">43.3%</td><td align="left" rowspan="1" colspan="1">19/63</td><td align="left" rowspan="1" colspan="1">30.2%</td></tr><tr><td align="left" style="padding-left:10%" colspan="7" rowspan="1">Body mass index, kg/m<sup>2</sup>
</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Mean&#x000b1;SD</td><td align="left" rowspan="1" colspan="1">28</td><td align="left" rowspan="1" colspan="1">5.3</td><td align="left" rowspan="1" colspan="1">26</td><td align="left" rowspan="1" colspan="1">4.2</td><td align="left" rowspan="1" colspan="1">27</td><td align="left" rowspan="1" colspan="1">4.9</td></tr><tr><td align="left" style="padding-left:10%" colspan="7" rowspan="1">New York Heart Association class</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">I&#x02013;II</td><td align="left" rowspan="1" colspan="1">19/33</td><td align="left" rowspan="1" colspan="1">57.6%</td><td align="left" rowspan="1" colspan="1">16/30</td><td align="left" rowspan="1" colspan="1">53.3%</td><td align="left" rowspan="1" colspan="1">35/63</td><td align="left" rowspan="1" colspan="1">55.5%</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">III&#x02013;IV</td><td align="left" rowspan="1" colspan="1">14/33</td><td align="left" rowspan="1" colspan="1">42.4%</td><td align="left" rowspan="1" colspan="1">14/30</td><td align="left" rowspan="1" colspan="1">46.7%</td><td align="left" rowspan="1" colspan="1">28/63</td><td align="left" rowspan="1" colspan="1">44.5%</td></tr><tr><td align="left" style="padding-left:10%" colspan="7" rowspan="1">Canadian Cardiovascular Society class</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Asymptomatic</td><td align="left" rowspan="1" colspan="1">24/33</td><td align="left" rowspan="1" colspan="1">72.7%</td><td align="left" rowspan="1" colspan="1">23/30</td><td align="left" rowspan="1" colspan="1">76.7%</td><td align="left" rowspan="1" colspan="1">47/63</td><td align="left" rowspan="1" colspan="1">74.6%</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">I&#x02013;II</td><td align="left" rowspan="1" colspan="1">7/33</td><td align="left" rowspan="1" colspan="1">21.2%</td><td align="left" rowspan="1" colspan="1">5/30</td><td align="left" rowspan="1" colspan="1">16.7%</td><td align="left" rowspan="1" colspan="1">12/63</td><td align="left" rowspan="1" colspan="1">18.0%</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">III&#x02013;IV</td><td align="left" rowspan="1" colspan="1">2/33</td><td align="left" rowspan="1" colspan="1">6.1%</td><td align="left" rowspan="1" colspan="1">2/30</td><td align="left" rowspan="1" colspan="1">6.6%</td><td align="left" rowspan="1" colspan="1">4/63</td><td align="left" rowspan="1" colspan="1">6.4%</td></tr><tr><td align="left" colspan="7" rowspan="1">Echocardiographic and angiographic results</td></tr><tr><td align="left" style="padding-left:10%" colspan="7" rowspan="1">Left ventricle function</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Good (&#x0003e;50%)</td><td align="left" rowspan="1" colspan="1">28/33</td><td align="left" rowspan="1" colspan="1">84.8%</td><td align="left" rowspan="1" colspan="1">23/30</td><td align="left" rowspan="1" colspan="1">76.7%</td><td align="left" rowspan="1" colspan="1">51/63</td><td align="left" rowspan="1" colspan="1">81.0%</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Moderate (30%&#x02013;50%)</td><td align="left" rowspan="1" colspan="1">4/33</td><td align="left" rowspan="1" colspan="1">12.1%</td><td align="left" rowspan="1" colspan="1">6/30</td><td align="left" rowspan="1" colspan="1">20.0%</td><td align="left" rowspan="1" colspan="1">10/63</td><td align="left" rowspan="1" colspan="1">15.9%</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Poor (&#x0003c;30%)</td><td align="left" rowspan="1" colspan="1">1/33</td><td align="left" rowspan="1" colspan="1">3.0%</td><td align="left" rowspan="1" colspan="1">1/30</td><td align="left" rowspan="1" colspan="1">3.3%</td><td align="left" rowspan="1" colspan="1">2/63</td><td align="left" rowspan="1" colspan="1">3.2%</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Valve disease alone</td><td align="left" rowspan="1" colspan="1">30/33</td><td align="left" rowspan="1" colspan="1">90.9%</td><td align="left" rowspan="1" colspan="1">24/30</td><td align="left" rowspan="1" colspan="1">80.0%</td><td align="left" rowspan="1" colspan="1">54/63</td><td align="left" rowspan="1" colspan="1">85.7%</td></tr><tr><td align="left" style="padding-left:10%" colspan="7" rowspan="1">Type of valve disease</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Aortic (S/R)</td><td align="left" rowspan="1" colspan="1">9 (7/2)</td><td align="left" rowspan="1" colspan="1">27.3%</td><td align="left" rowspan="1" colspan="1">15 (11/4)</td><td align="left" rowspan="1" colspan="1">50.0%</td><td align="left" rowspan="1" colspan="1">24 (18/6)</td><td align="left" rowspan="1" colspan="1">38.1%</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Mitral (S/R)</td><td align="left" rowspan="1" colspan="1">25 (8/17)</td><td align="left" rowspan="1" colspan="1">75.8%</td><td align="left" rowspan="1" colspan="1">16 (5/11)</td><td align="left" rowspan="1" colspan="1">53.3%</td><td align="left" rowspan="1" colspan="1">41 (13/28)</td><td align="left" rowspan="1" colspan="1">61.9%</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Valve and CAD disease</td><td align="left" rowspan="1" colspan="1">3/33</td><td align="left" rowspan="1" colspan="1">9.1%</td><td align="left" rowspan="1" colspan="1">6/30</td><td align="left" rowspan="1" colspan="1">20.0%</td><td align="left" rowspan="1" colspan="1">9/63</td><td align="left" rowspan="1" colspan="1">14.3%</td></tr><tr><td align="left" style="padding-left:10%" colspan="7" rowspan="1">Extent of CAD</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Single</td><td align="left" rowspan="1" colspan="1">0/33</td><td align="left" rowspan="1" colspan="1">0.0%</td><td align="left" rowspan="1" colspan="1">4/30</td><td align="left" rowspan="1" colspan="1">13.3%</td><td align="left" rowspan="1" colspan="1">4/63</td><td align="left" rowspan="1" colspan="1">6.3%</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Double</td><td align="left" rowspan="1" colspan="1">2/33</td><td align="left" rowspan="1" colspan="1">6.1%</td><td align="left" rowspan="1" colspan="1">0/30</td><td align="left" rowspan="1" colspan="1">0.0%</td><td align="left" rowspan="1" colspan="1">2/63</td><td align="left" rowspan="1" colspan="1">3.2%</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Triple</td><td align="left" rowspan="1" colspan="1">1/33</td><td align="left" rowspan="1" colspan="1">3.0%</td><td align="left" rowspan="1" colspan="1">2/30</td><td align="left" rowspan="1" colspan="1">6.7%</td><td align="left" rowspan="1" colspan="1">3/63</td><td align="left" rowspan="1" colspan="1">4.8%</td></tr><tr><td align="left" colspan="7" rowspan="1">Past medical history</td></tr><tr><td align="left" style="padding-left:10%" colspan="7" rowspan="1">Smoking status</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Smoker</td><td align="left" rowspan="1" colspan="1">2/33</td><td align="left" rowspan="1" colspan="1">6.1%</td><td align="left" rowspan="1" colspan="1">4/30</td><td align="left" rowspan="1" colspan="1">13.3%</td><td align="left" rowspan="1" colspan="1">6/63</td><td align="left" rowspan="1" colspan="1">9.5%</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Exsmoker</td><td align="left" rowspan="1" colspan="1">10/33</td><td align="left" rowspan="1" colspan="1">30.3%</td><td align="left" rowspan="1" colspan="1">13/30</td><td align="left" rowspan="1" colspan="1">43.3%</td><td align="left" rowspan="1" colspan="1">23/63</td><td align="left" rowspan="1" colspan="1">36.5%</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Nonsmoker</td><td align="left" rowspan="1" colspan="1">21/33</td><td align="left" rowspan="1" colspan="1">63.6%</td><td align="left" rowspan="1" colspan="1">13/30</td><td align="left" rowspan="1" colspan="1">43.3%</td><td align="left" rowspan="1" colspan="1">34/63</td><td align="left" rowspan="1" colspan="1">54.0%</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Asthma</td><td align="left" rowspan="1" colspan="1">2/33</td><td align="left" rowspan="1" colspan="1">6.1%</td><td align="left" rowspan="1" colspan="1">1/30</td><td align="left" rowspan="1" colspan="1">3.3%</td><td align="left" rowspan="1" colspan="1">3/63</td><td align="left" rowspan="1" colspan="1">4.8%</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Chronic obstructive pulmonary disease</td><td align="left" rowspan="1" colspan="1">0/33</td><td align="left" rowspan="1" colspan="1">0.0%</td><td align="left" rowspan="1" colspan="1">1/30</td><td align="left" rowspan="1" colspan="1">3.3%</td><td align="left" rowspan="1" colspan="1">1/63</td><td align="left" rowspan="1" colspan="1">1.6%</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Family history of lung disease</td><td align="left" rowspan="1" colspan="1">7/33</td><td align="left" rowspan="1" colspan="1">21.2%</td><td align="left" rowspan="1" colspan="1">4/30</td><td align="left" rowspan="1" colspan="1">13.3%</td><td align="left" rowspan="1" colspan="1">11/63</td><td align="left" rowspan="1" colspan="1">17.5%</td></tr><tr><td align="left" colspan="7" rowspan="1">Nonlung disease</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Treated hypertension</td><td align="left" rowspan="1" colspan="1">16/33</td><td align="left" rowspan="1" colspan="1">48.5%</td><td align="left" rowspan="1" colspan="1">16/30</td><td align="left" rowspan="1" colspan="1">53.3%</td><td align="left" rowspan="1" colspan="1">32/63</td><td align="left" rowspan="1" colspan="1">50.8%</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Hypercholesterolemia</td><td align="left" rowspan="1" colspan="1">11/33</td><td align="left" rowspan="1" colspan="1">33.3%</td><td align="left" rowspan="1" colspan="1">11/30</td><td align="left" rowspan="1" colspan="1">36.7%</td><td align="left" rowspan="1" colspan="1">22/63</td><td align="left" rowspan="1" colspan="1">34.9%</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Hypothyroidism</td><td align="left" rowspan="1" colspan="1">3/33</td><td align="left" rowspan="1" colspan="1">9.1%</td><td align="left" rowspan="1" colspan="1">1/30</td><td align="left" rowspan="1" colspan="1">3.3%</td><td align="left" rowspan="1" colspan="1">4/63</td><td align="left" rowspan="1" colspan="1">6.3%</td></tr><tr><td align="left" style="padding-left:10%" colspan="7" rowspan="1">Diabetes</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Insulin</td><td align="left" rowspan="1" colspan="1">1/33</td><td align="left" rowspan="1" colspan="1">3.0%</td><td align="left" rowspan="1" colspan="1">0/30</td><td align="left" rowspan="1" colspan="1">0.0%</td><td align="left" rowspan="1" colspan="1">1/63</td><td align="left" rowspan="1" colspan="1">1.6%</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Oral</td><td align="left" rowspan="1" colspan="1">3/33</td><td align="left" rowspan="1" colspan="1">9.1%</td><td align="left" rowspan="1" colspan="1">2/30</td><td align="left" rowspan="1" colspan="1">6.7%</td><td align="left" rowspan="1" colspan="1">5/63</td><td align="left" rowspan="1" colspan="1">7.9%</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Diet</td><td align="left" rowspan="1" colspan="1">2/33</td><td align="left" rowspan="1" colspan="1">6.1%</td><td align="left" rowspan="1" colspan="1">0/30</td><td align="left" rowspan="1" colspan="1">0.0%</td><td align="left" rowspan="1" colspan="1">2/63</td><td align="left" rowspan="1" colspan="1">3.2%</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Cerebral vascular accident/transient ischemic attack</td><td align="left" rowspan="1" colspan="1">2/33</td><td align="left" rowspan="1" colspan="1">6.1%</td><td align="left" rowspan="1" colspan="1">1/30</td><td align="left" rowspan="1" colspan="1">3.3%</td><td align="left" rowspan="1" colspan="1">3/63</td><td align="left" rowspan="1" colspan="1">4.8%</td></tr><tr><td align="left" style="padding-left:10%" colspan="7" rowspan="1">EuroSCORE</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Mean&#x000b1;SD</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">1.8</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">1.5</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">1.8</td></tr><tr><td align="left" style="padding-left:10%" colspan="7" rowspan="1">Arrhythmias</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Atrial fibrillation</td><td align="left" rowspan="1" colspan="1">12/33</td><td align="left" rowspan="1" colspan="1">36.4%</td><td align="left" rowspan="1" colspan="1">10/30</td><td align="left" rowspan="1" colspan="1">33.3%</td><td align="left" rowspan="1" colspan="1">22/63</td><td align="left" rowspan="1" colspan="1">34.9%</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Block</td><td align="left" rowspan="1" colspan="1">0/33</td><td align="left" rowspan="1" colspan="1">0.0%</td><td align="left" rowspan="1" colspan="1">1/30</td><td align="left" rowspan="1" colspan="1">3.3%</td><td align="left" rowspan="1" colspan="1">1/63</td><td align="left" rowspan="1" colspan="1">1.6%</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Peptic ulceration</td><td align="left" rowspan="1" colspan="1">1/33</td><td align="left" rowspan="1" colspan="1">3.0%</td><td align="left" rowspan="1" colspan="1">0/30</td><td align="left" rowspan="1" colspan="1">0.0%</td><td align="left" rowspan="1" colspan="1">1/63</td><td align="left" rowspan="1" colspan="1">1.6%</td></tr><tr><td align="left" style="padding-left:10%" colspan="7" rowspan="1">Operative priority</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Elective</td><td align="left" rowspan="1" colspan="1">32/33</td><td align="left" rowspan="1" colspan="1">97.0%</td><td align="left" rowspan="1" colspan="1">27/30</td><td align="left" rowspan="1" colspan="1">90.0%</td><td align="left" rowspan="1" colspan="1">59/63</td><td align="left" rowspan="1" colspan="1">93.7%</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Urgent</td><td align="left" rowspan="1" colspan="1">1/33</td><td align="left" rowspan="1" colspan="1">3.0%</td><td align="left" rowspan="1" colspan="1">3/30</td><td align="left" rowspan="1" colspan="1">10.0%</td><td align="left" rowspan="1" colspan="1">4/63</td><td align="left" rowspan="1" colspan="1">6.3%</td></tr></tbody></table><table-wrap-foot id="jah310122-ntgp-0002"><fn id="jah310122-note-0004"><p>Missing data: body mass index: data missing for 1 patient (0, 1); EuroSCORE: data missing for 2 patients (0, 2). CAD indicates coronary artery disease; LFV, low frequency ventilation; and S/R, stenosis/regurgitation.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="jah310122-tbl-0002" content-type="Table"><label>Table 2</label><caption><p>Operative Details</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="2" colspan="1"/><th align="left" colspan="2" rowspan="1">Randomized to LFV (n=33)</th><th align="left" colspan="2" rowspan="1">Randomized to usual care (n=30)</th><th align="left" colspan="2" rowspan="1">Overall (n=63)</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1">n</th><th align="left" rowspan="1" colspan="1">%</th><th align="left" rowspan="1" colspan="1">n</th><th align="left" rowspan="1" colspan="1">%</th><th align="left" rowspan="1" colspan="1">n</th><th align="left" rowspan="1" colspan="1">%</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Bypass data</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Operation time (min)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Median (IQR)</td><td align="left" rowspan="1" colspan="1">280</td><td align="left" rowspan="1" colspan="1">(245.0&#x02013;305.0)</td><td align="left" rowspan="1" colspan="1">240</td><td align="left" rowspan="1" colspan="1">(215.0&#x02013;300.0)</td><td align="left" rowspan="1" colspan="1">265</td><td align="left" rowspan="1" colspan="1">(225.0&#x02013;305.0)</td></tr><tr><td align="left" style="padding-left:10%" colspan="7" rowspan="1">Cardiopulmonary bypass time (min)</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Median (IQR)</td><td align="left" rowspan="1" colspan="1">115</td><td align="left" rowspan="1" colspan="1">(102.0&#x02013;146.0)</td><td align="left" rowspan="1" colspan="1">112</td><td align="left" rowspan="1" colspan="1">(94.0&#x02013;129.0)</td><td align="left" rowspan="1" colspan="1">112</td><td align="left" rowspan="1" colspan="1">(98.0&#x02013;131.0)</td></tr><tr><td align="left" style="padding-left:10%" colspan="7" rowspan="1">Cardioplegic arrest time (min)</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Median (IQR)</td><td align="left" rowspan="1" colspan="1">84</td><td align="left" rowspan="1" colspan="1">(72.0&#x02013;101.0)</td><td align="left" rowspan="1" colspan="1">79</td><td align="left" rowspan="1" colspan="1">(67.0&#x02013;92.0)</td><td align="left" rowspan="1" colspan="1">81</td><td align="left" rowspan="1" colspan="1">(67.0&#x02013;100.0)</td></tr><tr><td align="left" style="padding-left:10%" colspan="7" rowspan="1">Lowest hematocrit</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Median (IQR)</td><td align="left" rowspan="1" colspan="1">28</td><td align="left" rowspan="1" colspan="1">(23.2&#x02013;30.5)</td><td align="left" rowspan="1" colspan="1">26</td><td align="left" rowspan="1" colspan="1">(23.2&#x02013;28.0)</td><td align="left" rowspan="1" colspan="1">27</td><td align="left" rowspan="1" colspan="1">(23.2&#x02013;29.3)</td></tr><tr><td align="left" style="padding-left:10%" colspan="7" rowspan="1">Lowest core temperature</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Median (IQR)</td><td align="left" rowspan="1" colspan="1">32</td><td align="left" rowspan="1" colspan="1">(31.8&#x02013;32.0)</td><td align="left" rowspan="1" colspan="1">32</td><td align="left" rowspan="1" colspan="1">(31.9&#x02013;32.0)</td><td align="left" rowspan="1" colspan="1">32</td><td align="left" rowspan="1" colspan="1">(31.9&#x02013;32.0)</td></tr><tr><td align="left" style="padding-left:10%" colspan="7" rowspan="1">Blood loss<xref rid="jah310122-note-0006" ref-type="table-fn">*</xref>
</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Median (IQR)</td><td align="left" rowspan="1" colspan="1">400</td><td align="left" rowspan="1" colspan="1">(300.0&#x02013;850.0)</td><td align="left" rowspan="1" colspan="1">525</td><td align="left" rowspan="1" colspan="1">(375.0&#x02013;650.0)</td><td align="left" rowspan="1" colspan="1">475</td><td align="left" rowspan="1" colspan="1">(325.0&#x02013;700.0)</td></tr><tr><td align="left" colspan="7" rowspan="1">Blood saving techniques</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Tranexamic acid</td><td align="left" rowspan="1" colspan="1">33/33</td><td align="left" rowspan="1" colspan="1">100.0%</td><td align="left" rowspan="1" colspan="1">29/30</td><td align="left" rowspan="1" colspan="1">96.7%</td><td align="left" rowspan="1" colspan="1">62/63</td><td align="left" rowspan="1" colspan="1">98.4%</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Use of cell saver</td><td align="left" rowspan="1" colspan="1">5/33</td><td align="left" rowspan="1" colspan="1">15.2%</td><td align="left" rowspan="1" colspan="1">4/30</td><td align="left" rowspan="1" colspan="1">13.3%</td><td align="left" rowspan="1" colspan="1">9/63</td><td align="left" rowspan="1" colspan="1">14.3%</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Red blood cell transfusion</td><td align="left" rowspan="1" colspan="1">9/33</td><td align="left" rowspan="1" colspan="1">27.3%</td><td align="left" rowspan="1" colspan="1">6/30</td><td align="left" rowspan="1" colspan="1">20.0%</td><td align="left" rowspan="1" colspan="1">48/63</td><td align="left" rowspan="1" colspan="1">23.8%</td></tr><tr><td align="left" style="padding-left:10%" colspan="7" rowspan="1">Units transfused</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Median (IQR)</td><td align="left" rowspan="1" colspan="1">1.0</td><td align="left" rowspan="1" colspan="1">(1.0&#x02013;2.0)</td><td align="left" rowspan="1" colspan="1">1.5</td><td align="left" rowspan="1" colspan="1">(1.0&#x02013;3.0)</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">(1.0&#x02013;2.0)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Fresh frozen plasma transfusion</td><td align="left" rowspan="1" colspan="1">4/33</td><td align="left" rowspan="1" colspan="1">12.1%</td><td align="left" rowspan="1" colspan="1">2/30</td><td align="left" rowspan="1" colspan="1">6.7%</td><td align="left" rowspan="1" colspan="1">6/63</td><td align="left" rowspan="1" colspan="1">9.5%</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Median (IQR)</td><td align="left" rowspan="1" colspan="1">3.5</td><td align="left" rowspan="1" colspan="1">(2.5&#x02013;4.0)</td><td align="left" rowspan="1" colspan="1">1.5</td><td align="left" rowspan="1" colspan="1">(1.0&#x02013;2.0)</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">(2.0&#x02013;4.0)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Platelet transfusion</td><td align="left" rowspan="1" colspan="1">5/33</td><td align="left" rowspan="1" colspan="1">15.2%</td><td align="left" rowspan="1" colspan="1">5/30</td><td align="left" rowspan="1" colspan="1">16.7%</td><td align="left" rowspan="1" colspan="1">10/63</td><td align="left" rowspan="1" colspan="1">15.9%</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Median (IQR)</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">(1.0&#x02013;2.0)</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">(1.0&#x02013;1.0)</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">(1.0&#x02013;2.0)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Activated factor VII</td><td align="left" rowspan="1" colspan="1">1/33</td><td align="left" rowspan="1" colspan="1">3.0%</td><td align="left" rowspan="1" colspan="1">0/30</td><td align="left" rowspan="1" colspan="1">0.0%</td><td align="left" rowspan="1" colspan="1">1/63</td><td align="left" rowspan="1" colspan="1">1.6%</td></tr><tr><td align="left" colspan="7" rowspan="1">Intraoperative arrythmias</td></tr><tr><td align="left" style="padding-left:10%" colspan="7" rowspan="1">Arrhythmias on removal of cross clamp</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Atrioventricular block</td><td align="left" rowspan="1" colspan="1">7/31</td><td align="left" rowspan="1" colspan="1">22.6%</td><td align="left" rowspan="1" colspan="1">6/30</td><td align="left" rowspan="1" colspan="1">20.0%</td><td align="left" rowspan="1" colspan="1">13/61</td><td align="left" rowspan="1" colspan="1">21.3%</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Atrial fibrillation/flutter</td><td align="left" rowspan="1" colspan="1">6/31</td><td align="left" rowspan="1" colspan="1">19.4%</td><td align="left" rowspan="1" colspan="1">8/30</td><td align="left" rowspan="1" colspan="1">26.7%</td><td align="left" rowspan="1" colspan="1">14/61</td><td align="left" rowspan="1" colspan="1">23.0%</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Ventricular tachyarrhythmia/ventricular fibrillation</td><td align="left" rowspan="1" colspan="1">6/31</td><td align="left" rowspan="1" colspan="1">19.4%</td><td align="left" rowspan="1" colspan="1">2/30</td><td align="left" rowspan="1" colspan="1">6.6%</td><td align="left" rowspan="1" colspan="1">3/61</td><td align="left" rowspan="1" colspan="1">4.9%</td></tr><tr><td align="left" style="padding-left:10%" colspan="7" rowspan="1">Temporary pacing</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Single chamber</td><td align="left" rowspan="1" colspan="1">11/33</td><td align="left" rowspan="1" colspan="1">33.3%</td><td align="left" rowspan="1" colspan="1">10/30</td><td align="left" rowspan="1" colspan="1">33.3%</td><td align="left" rowspan="1" colspan="1">21/63</td><td align="left" rowspan="1" colspan="1">33.3%</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Dual chamber</td><td align="left" rowspan="1" colspan="1">13/33</td><td align="left" rowspan="1" colspan="1">39.4%</td><td align="left" rowspan="1" colspan="1">10/30</td><td align="left" rowspan="1" colspan="1">33.3%</td><td align="left" rowspan="1" colspan="1">23/63</td><td align="left" rowspan="1" colspan="1">36.5%</td></tr><tr><td align="left" colspan="7" rowspan="1">Other intraoperative details</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Need for insulin infusion</td><td align="left" rowspan="1" colspan="1">10/33</td><td align="left" rowspan="1" colspan="1">30.3%</td><td align="left" rowspan="1" colspan="1">3/30</td><td align="left" rowspan="1" colspan="1">10.0%</td><td align="left" rowspan="1" colspan="1">13/63</td><td align="left" rowspan="1" colspan="1">20.6%</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Need for mild inotropes</td><td align="left" rowspan="1" colspan="1">9/33</td><td align="left" rowspan="1" colspan="1">27.3%</td><td align="left" rowspan="1" colspan="1">4/30</td><td align="left" rowspan="1" colspan="1">13.3%</td><td align="left" rowspan="1" colspan="1">13/63</td><td align="left" rowspan="1" colspan="1">20.6%</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Need for noradrenaline</td><td align="left" rowspan="1" colspan="1">12/33</td><td align="left" rowspan="1" colspan="1">36.4%</td><td align="left" rowspan="1" colspan="1">5/30</td><td align="left" rowspan="1" colspan="1">16.7%</td><td align="left" rowspan="1" colspan="1">17/63</td><td align="left" rowspan="1" colspan="1">27.0%</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Need for vasodilator</td><td align="left" rowspan="1" colspan="1">2/33</td><td align="left" rowspan="1" colspan="1">6.1%</td><td align="left" rowspan="1" colspan="1">1/30</td><td align="left" rowspan="1" colspan="1">3.3%</td><td align="left" rowspan="1" colspan="1">3/63</td><td align="left" rowspan="1" colspan="1">4.8%</td></tr><tr><td align="left" colspan="7" rowspan="1">Type of valve surgery</td></tr><tr><td align="left" style="padding-left:10%" colspan="7" rowspan="1">Aortic valve (n=24)</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Repaired</td><td align="left" rowspan="1" colspan="1">0/33</td><td align="left" rowspan="1" colspan="1">0.0%</td><td align="left" rowspan="1" colspan="1">0/30</td><td align="left" rowspan="1" colspan="1">0.0%</td><td align="left" rowspan="1" colspan="1">0/63</td><td align="left" rowspan="1" colspan="1">0.0%</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Replaced</td><td align="left" rowspan="1" colspan="1">9/33</td><td align="left" rowspan="1" colspan="1">27.3%</td><td align="left" rowspan="1" colspan="1">15/30</td><td align="left" rowspan="1" colspan="1">50.0%</td><td align="left" rowspan="1" colspan="1">24/63</td><td align="left" rowspan="1" colspan="1">38.1%</td></tr><tr><td align="left" style="padding-left:10%" colspan="7" rowspan="1">Mitral valve (n=41)</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Repaired</td><td align="left" rowspan="1" colspan="1">9/33</td><td align="left" rowspan="1" colspan="1">27.3%</td><td align="left" rowspan="1" colspan="1">4/30</td><td align="left" rowspan="1" colspan="1">13.3%</td><td align="left" rowspan="1" colspan="1">13/63</td><td align="left" rowspan="1" colspan="1">20.6%</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Replaced</td><td align="left" rowspan="1" colspan="1">16/33</td><td align="left" rowspan="1" colspan="1">48.5%</td><td align="left" rowspan="1" colspan="1">12/30</td><td align="left" rowspan="1" colspan="1">40.0%</td><td align="left" rowspan="1" colspan="1">28/63</td><td align="left" rowspan="1" colspan="1">44.4%</td></tr></tbody></table><table-wrap-foot id="jah310122-ntgp-0003"><fn id="jah310122-note-0005"><p>IQR indicates interquartile range; and LFV, low frequency ventilation.</p></fn><fn id="jah310122-note-0006"><label>*</label><p>At first 12&#x02009;h after surgery.</p></fn></table-wrap-foot></table-wrap><p>Overall, 41/63 patients had MV surgery and 24/63 had aortic valve surgery, with similar distribution of repair/replacement rates between both groups. Only 9/63 patients required some bypass grafting on top of their valvular surgery due to concomitant severe coronary disease. of the 63 patients, 29 were current or exsmokers with similar distribution between groups (Table&#x000a0;<xref rid="jah310122-tbl-0002" ref-type="table">2</xref>). Baseline distribution of all medications, including those needed to treat chronic lung disease are shown in Table&#x000a0;<xref rid="jah310122-supitem-0001" ref-type="supplementary-material">S2</xref>. In addition, baseline FVC, FEV1, and FEV1/FVC ratio did not differ between groups (Table&#x000a0;<xref rid="jah310122-tbl-0003" ref-type="table">3</xref>). There were trends for mean EuroSCORE to be slightly higher in the LFV group, whereas diabetes and MV disease were slightly higher in the LFV group. CPB time did not differ between groups with mean LFV duration being 115&#x02009;minutes. Duration of surgery was 40&#x02009;minutes longer in the LFV group (Table&#x000a0;<xref rid="jah310122-tbl-0002" ref-type="table">2</xref>).</p><table-wrap position="float" id="jah310122-tbl-0003" content-type="Table"><label>Table 3</label><caption><p>Secondary Functional Outcome: Serial Pulmonary Function Tests</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="2" colspan="1"/><th align="left" colspan="2" rowspan="1">Randomized to LFV (n=33)</th><th align="left" colspan="2" rowspan="1">Randomized to usual care (n=30)</th><th align="left" rowspan="2" colspan="1">Effect<sup>1</sup> MD (95% CI)*</th><th align="left" rowspan="2" colspan="1">
<italic toggle="yes">P</italic> value</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1">Mean</th><th align="left" rowspan="1" colspan="1">SD</th><th align="left" rowspan="1" colspan="1">Mean</th><th align="left" rowspan="1" colspan="1">SD</th></tr></thead><tbody><tr><td align="left" colspan="7" rowspan="1">FVC</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Before surgery</td><td align="left" rowspan="1" colspan="1">3.52</td><td align="left" rowspan="1" colspan="1">0.90</td><td align="left" rowspan="1" colspan="1">3.24</td><td align="left" rowspan="1" colspan="1">1.19</td><td align="left" rowspan="1" colspan="1">&#x02026;</td><td align="left" rowspan="1" colspan="1">&#x02026;</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Before discharge</td><td align="left" rowspan="1" colspan="1">2.16</td><td align="left" rowspan="1" colspan="1">0.47</td><td align="left" rowspan="1" colspan="1">2.24</td><td align="left" rowspan="1" colspan="1">0.77</td><td align="left" rowspan="1" colspan="1">&#x02026;</td><td align="left" rowspan="1" colspan="1">&#x02026;</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">6&#x02013;8&#x02009;wk post discharge</td><td align="left" rowspan="1" colspan="1">3.29</td><td align="left" rowspan="1" colspan="1">0.86</td><td align="left" rowspan="1" colspan="1">3.26</td><td align="left" rowspan="1" colspan="1">1.03</td><td align="left" rowspan="1" colspan="1">&#x02026;</td><td align="left" rowspan="1" colspan="1">&#x02026;</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Treatment&#x000d7;Time interaction</td><td align="left" rowspan="1" colspan="1">&#x02026;</td><td align="left" rowspan="1" colspan="1">&#x02026;</td><td align="left" rowspan="1" colspan="1">&#x02026;</td><td align="left" rowspan="1" colspan="1">&#x02026;</td><td align="left" rowspan="1" colspan="1">&#x02026;</td><td align="left" rowspan="1" colspan="1">0.95</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Overall</td><td align="left" rowspan="1" colspan="1">&#x02026;</td><td align="left" rowspan="1" colspan="1">&#x02026;</td><td align="left" rowspan="1" colspan="1">&#x02026;</td><td align="left" rowspan="1" colspan="1">&#x02026;</td><td align="left" rowspan="1" colspan="1">&#x02212;0.191 (&#x02212;0.394 to 0.012)</td><td align="left" rowspan="1" colspan="1">0.05</td></tr><tr><td align="left" colspan="7" rowspan="1">FEV1</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Before surgery</td><td align="left" rowspan="1" colspan="1">2.60</td><td align="left" rowspan="1" colspan="1">0.69</td><td align="left" rowspan="1" colspan="1">2.30</td><td align="left" rowspan="1" colspan="1">0.79</td><td align="left" rowspan="1" colspan="1">&#x02026;</td><td align="left" rowspan="1" colspan="1">&#x02026;</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Before discharge**</td><td align="left" rowspan="1" colspan="1">1.60</td><td align="left" rowspan="1" colspan="1">0.39</td><td align="left" rowspan="1" colspan="1">1.60</td><td align="left" rowspan="1" colspan="1">0.55</td><td align="left" rowspan="1" colspan="1">&#x02026;</td><td align="left" rowspan="1" colspan="1">&#x02026;</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">6&#x02013;8&#x02009;wk post discharge<sup>&#x02020;</sup>
</td><td align="left" rowspan="1" colspan="1">2.47</td><td align="left" rowspan="1" colspan="1">0.67</td><td align="left" rowspan="1" colspan="1">2.22</td><td align="left" rowspan="1" colspan="1">0.76</td><td align="left" rowspan="1" colspan="1">&#x02026;</td><td align="left" rowspan="1" colspan="1">&#x02026;</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Treatment&#x000d7;Time interaction</td><td align="left" rowspan="1" colspan="1">&#x02026;</td><td align="left" rowspan="1" colspan="1">&#x02026;</td><td align="left" rowspan="1" colspan="1">&#x02026;</td><td align="left" rowspan="1" colspan="1">&#x02026;</td><td align="left" rowspan="1" colspan="1">&#x02026;</td><td align="left" rowspan="1" colspan="1">0.33</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Overall</td><td align="left" rowspan="1" colspan="1">&#x02026;</td><td align="left" rowspan="1" colspan="1">&#x02026;</td><td align="left" rowspan="1" colspan="1">&#x02026;</td><td align="left" rowspan="1" colspan="1">&#x02026;</td><td align="left" rowspan="1" colspan="1">&#x02212;0.135 (&#x02212;0.290 to 0.019)</td><td align="left" rowspan="1" colspan="1">0.08</td></tr><tr><td align="left" colspan="7" rowspan="1">FEV1/FVC</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Before surgery</td><td align="left" rowspan="1" colspan="1">0.74</td><td align="left" rowspan="1" colspan="1">0.08</td><td align="left" rowspan="1" colspan="1">0.72</td><td align="left" rowspan="1" colspan="1">0.11</td><td align="left" rowspan="1" colspan="1">&#x02026;</td><td align="left" rowspan="1" colspan="1">&#x02026;</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Before discharge*</td><td align="left" rowspan="1" colspan="1">0.74</td><td align="left" rowspan="1" colspan="1">0.09</td><td align="left" rowspan="1" colspan="1">0.73</td><td align="left" rowspan="1" colspan="1">0.13</td><td align="left" rowspan="1" colspan="1">&#x02212;0.0005 (&#x02212;0.044 to 0.043)</td><td align="left" rowspan="1" colspan="1">0.98</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">6&#x02013;8&#x02009;wk post discharge<sup>&#x02020;</sup>
</td><td align="left" rowspan="1" colspan="1">0.75</td><td align="left" rowspan="1" colspan="1">0.10</td><td align="left" rowspan="1" colspan="1">0.68</td><td align="left" rowspan="1" colspan="1">0.10</td><td align="left" rowspan="1" colspan="1">0.050 (0.007 to 0.093)</td><td align="left" rowspan="1" colspan="1">0.02</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Treatment&#x000d7;time interaction</td><td align="left" rowspan="1" colspan="1">&#x02026;</td><td align="left" rowspan="1" colspan="1">&#x02026;</td><td align="left" rowspan="1" colspan="1">&#x02026;</td><td align="left" rowspan="1" colspan="1">&#x02026;</td><td align="left" rowspan="1" colspan="1">&#x02026;</td><td align="left" rowspan="1" colspan="1">0.04</td></tr><tr><td align="left" rowspan="1" colspan="1">Alveolar&#x02010;arterial oxygenation gradient</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Preoperative<sup>&#x02021;</sup>
</td><td align="left" rowspan="1" colspan="1">6.59</td><td align="left" rowspan="1" colspan="1">86.02</td><td align="left" rowspan="1" colspan="1">17.92</td><td align="left" rowspan="1" colspan="1">16.08</td><td align="left" rowspan="1" colspan="1">&#x02026;</td><td align="left" rowspan="1" colspan="1">&#x02026;</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Postinduction<sup>&#x000a7;</sup>
</td><td align="left" rowspan="1" colspan="1">146.46</td><td align="left" rowspan="1" colspan="1">76.10</td><td align="left" rowspan="1" colspan="1">128.08</td><td align="left" rowspan="1" colspan="1">93.33</td><td align="left" rowspan="1" colspan="1">&#x02026;</td><td align="left" rowspan="1" colspan="1">&#x02026;</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">10&#x02009;min post end of CPB<sup>||</sup>
</td><td align="left" rowspan="1" colspan="1">125.13</td><td align="left" rowspan="1" colspan="1">81.89</td><td align="left" rowspan="1" colspan="1">164.44</td><td align="left" rowspan="1" colspan="1">111.40</td><td align="left" rowspan="1" colspan="1">&#x02026;</td><td align="left" rowspan="1" colspan="1">&#x02026;</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Before chest closure<sup>#</sup>
</td><td align="left" rowspan="1" colspan="1">150.40</td><td align="left" rowspan="1" colspan="1">67.84</td><td align="left" rowspan="1" colspan="1">157.62</td><td align="left" rowspan="1" colspan="1">89.62</td><td align="left" rowspan="1" colspan="1">&#x02026;</td><td align="left" rowspan="1" colspan="1">&#x02026;</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">2&#x02009;h post CPB<sup>&#x000a7;</sup>
</td><td align="left" rowspan="1" colspan="1">160.27</td><td align="left" rowspan="1" colspan="1">70.64</td><td align="left" rowspan="1" colspan="1">150.22</td><td align="left" rowspan="1" colspan="1">96.96</td><td align="left" rowspan="1" colspan="1">&#x02026;</td><td align="left" rowspan="1" colspan="1">&#x02026;</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">4&#x02009;h post CPB**</td><td align="left" rowspan="1" colspan="1">159.24</td><td align="left" rowspan="1" colspan="1">74.31</td><td align="left" rowspan="1" colspan="1">146.17</td><td align="left" rowspan="1" colspan="1">97.14</td><td align="left" rowspan="1" colspan="1">&#x02026;</td><td align="left" rowspan="1" colspan="1">&#x02026;</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">12&#x02009;h post CPB<sup>&#x02020;&#x02020;</sup>
</td><td align="left" rowspan="1" colspan="1">238.70</td><td align="left" rowspan="1" colspan="1">182.46</td><td align="left" rowspan="1" colspan="1">229.77</td><td align="left" rowspan="1" colspan="1">190.50</td><td align="left" rowspan="1" colspan="1">&#x02026;</td><td align="left" rowspan="1" colspan="1">&#x02026;</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Treatment&#x000d7;time interaction</td><td align="left" rowspan="1" colspan="1">&#x02026;</td><td align="left" rowspan="1" colspan="1">&#x02026;</td><td align="left" rowspan="1" colspan="1">&#x02026;</td><td align="left" rowspan="1" colspan="1">&#x02026;</td><td align="left" rowspan="1" colspan="1">&#x02026;</td><td align="left" rowspan="1" colspan="1">0.45</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Overall</td><td align="left" rowspan="1" colspan="1">&#x02026;</td><td align="left" rowspan="1" colspan="1">&#x02026;</td><td align="left" rowspan="1" colspan="1">&#x02026;</td><td align="left" rowspan="1" colspan="1">&#x02026;</td><td align="left" rowspan="1" colspan="1">6.755 (&#x02212;25.192 to 38.702)</td><td align="left" rowspan="1" colspan="1">0.65</td></tr><tr><td align="left" colspan="7" rowspan="1">Respiratory index</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Preoperative<sup>&#x02021;</sup>
</td><td align="left" rowspan="1" colspan="1">0.27</td><td align="left" rowspan="1" colspan="1">0.28</td><td align="left" rowspan="1" colspan="1">0.25</td><td align="left" rowspan="1" colspan="1">0.19</td><td align="left" rowspan="1" colspan="1">&#x02026;</td><td align="left" rowspan="1" colspan="1">&#x02026;</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Postinduction<sup>&#x000a7;</sup>
</td><td align="left" rowspan="1" colspan="1">1.01</td><td align="left" rowspan="1" colspan="1">0.98</td><td align="left" rowspan="1" colspan="1">0.74</td><td align="left" rowspan="1" colspan="1">0.76</td><td align="left" rowspan="1" colspan="1">0.252 (&#x02212;0.193 to 0.697)</td><td align="left" rowspan="1" colspan="1">0.25</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">10&#x02009;min post end of CPB<sup>||</sup>
</td><td align="left" rowspan="1" colspan="1">0.77</td><td align="left" rowspan="1" colspan="1">0.84</td><td align="left" rowspan="1" colspan="1">1.40</td><td align="left" rowspan="1" colspan="1">1.50</td><td align="left" rowspan="1" colspan="1">&#x02212;0.610 (&#x02212;1.236 to 0.0147)</td><td align="left" rowspan="1" colspan="1">0.05</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Before chest closure<sup>#</sup>
</td><td align="left" rowspan="1" colspan="1">1.11</td><td align="left" rowspan="1" colspan="1">0.88</td><td align="left" rowspan="1" colspan="1">1.27</td><td align="left" rowspan="1" colspan="1">1.19</td><td align="left" rowspan="1" colspan="1">&#x02212;0.132 (&#x02212;0.673 to 0.409)</td><td align="left" rowspan="1" colspan="1">0.62</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">2&#x02009;h post CPB<sup>&#x000a7;</sup>
</td><td align="left" rowspan="1" colspan="1">1.49</td><td align="left" rowspan="1" colspan="1">1.23</td><td align="left" rowspan="1" colspan="1">1.17</td><td align="left" rowspan="1" colspan="1">0.95</td><td align="left" rowspan="1" colspan="1">0.273 (&#x02212;0.272 to 0.818)</td><td align="left" rowspan="1" colspan="1">0.31</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">4&#x02009;h post CPB**</td><td align="left" rowspan="1" colspan="1">1.17</td><td align="left" rowspan="1" colspan="1">0.80</td><td align="left" rowspan="1" colspan="1">1.03</td><td align="left" rowspan="1" colspan="1">0.75</td><td align="left" rowspan="1" colspan="1">0.136 (&#x02212;0.253 to 0.524)</td><td align="left" rowspan="1" colspan="1">0.48</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">12&#x02009;h post CPB<sup>&#x02020;&#x02020;</sup>
</td><td align="left" rowspan="1" colspan="1">1.90</td><td align="left" rowspan="1" colspan="1">1.67</td><td align="left" rowspan="1" colspan="1">2.20</td><td align="left" rowspan="1" colspan="1">2.81</td><td align="left" rowspan="1" colspan="1">0.023 (&#x02212;0.818 to 0.863)</td><td align="left" rowspan="1" colspan="1">0.95</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Treatment&#x000d7;time interaction</td><td align="left" rowspan="1" colspan="1">&#x02026;</td><td align="left" rowspan="1" colspan="1">&#x02026;</td><td align="left" rowspan="1" colspan="1">&#x02026;</td><td align="left" rowspan="1" colspan="1">&#x02026;</td><td align="left" rowspan="1" colspan="1">&#x02026;</td><td align="left" rowspan="1" colspan="1">0.05</td></tr><tr><td align="left" colspan="7" rowspan="1">Peak airway pressure</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Presternotomy<sup>&#x02021;&#x02021;</sup>
</td><td align="left" rowspan="1" colspan="1">18.53</td><td align="left" rowspan="1" colspan="1">4.64</td><td align="left" rowspan="1" colspan="1">18.24</td><td align="left" rowspan="1" colspan="1">3.72</td><td align="left" rowspan="1" colspan="1">&#x02026;</td><td align="left" rowspan="1" colspan="1">&#x02026;</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">2&#x02009;h post CPB<sup>&#x000a7;&#x000a7;</sup>
</td><td align="left" rowspan="1" colspan="1">16.62</td><td align="left" rowspan="1" colspan="1">3.38</td><td align="left" rowspan="1" colspan="1">17.64</td><td align="left" rowspan="1" colspan="1">3.73</td><td align="left" rowspan="1" colspan="1">&#x02026;</td><td align="left" rowspan="1" colspan="1">&#x02026;</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">4&#x02009;h post CPB<sup>||||</sup>
</td><td align="left" rowspan="1" colspan="1">17.54</td><td align="left" rowspan="1" colspan="1">3.38</td><td align="left" rowspan="1" colspan="1">18.67</td><td align="left" rowspan="1" colspan="1">3.99</td><td align="left" rowspan="1" colspan="1">&#x02026;</td><td align="left" rowspan="1" colspan="1">&#x02026;</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Treatment&#x000d7;time interaction</td><td align="left" rowspan="1" colspan="1">&#x02026;</td><td align="left" rowspan="1" colspan="1">&#x02026;</td><td align="left" rowspan="1" colspan="1">&#x02026;</td><td align="left" rowspan="1" colspan="1">&#x02026;</td><td align="left" rowspan="1" colspan="1">&#x02026;</td><td align="left" rowspan="1" colspan="1">0.91</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Overall</td><td align="left" rowspan="1" colspan="1">&#x02026;</td><td align="left" rowspan="1" colspan="1">&#x02026;</td><td align="left" rowspan="1" colspan="1">&#x02026;</td><td align="left" rowspan="1" colspan="1">&#x02026;</td><td align="left" rowspan="1" colspan="1">&#x02212;0.813 (&#x02212;2.3448 to 0.718)</td><td align="left" rowspan="1" colspan="1">0.28</td></tr><tr><td align="left" colspan="7" rowspan="1">Left atrium/right atrium white blood cell count</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Before institution of CPB<sup>##</sup>
</td><td align="left" rowspan="1" colspan="1">0.91</td><td align="left" rowspan="1" colspan="1">0.15</td><td align="left" rowspan="1" colspan="1">0.98</td><td align="left" rowspan="1" colspan="1">0.13</td><td align="left" rowspan="1" colspan="1">&#x02026;</td><td align="left" rowspan="1" colspan="1">&#x02026;</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Weaning from CPB<sup>&#x000a7;</sup>
</td><td align="left" rowspan="1" colspan="1">0.94</td><td align="left" rowspan="1" colspan="1">0.09</td><td align="left" rowspan="1" colspan="1">0.96</td><td align="left" rowspan="1" colspan="1">0.10</td><td align="left" rowspan="1" colspan="1">&#x02026;</td><td align="left" rowspan="1" colspan="1">&#x02026;</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Overall</td><td align="left" rowspan="1" colspan="1">&#x02026;</td><td align="left" rowspan="1" colspan="1">&#x02026;</td><td align="left" rowspan="1" colspan="1">&#x02026;</td><td align="left" rowspan="1" colspan="1">&#x02026;</td><td align="left" rowspan="1" colspan="1">&#x02212;0.027 (&#x02212;0.074 to 0.021)</td><td align="left" rowspan="1" colspan="1">0.27</td></tr></tbody></table><table-wrap-foot id="jah310122-ntgp-0004"><fn id="jah310122-note-0007"><p>Treatment effect estimates are given either for each time point or overall, depending on whether a treatment&#x000d7;time interaction term is found to be required in the model. Missing data (LFV, usual care): CPB indicates cardiopulmonary bypass; FEV<sub>1</sub>, forced expiratory volume after 1&#x02009;s; FVC, forced vital capacity; LFV, low frequency ventilation; and MD, mean difference.</p></fn><fn id="jah310122-note-2007"><p>*8(6, 2)</p><p>
<sup>&#x02020;</sup>8(5, 3)</p><p>
<sup>&#x02021;</sup>1(0, 1)</p><p>
<sup>&#x000a7;</sup>2(1, 1)</p><p>
<sup>||</sup>4(3, 1)</p><p>
<sup>#</sup>5(3, 2)</p><p>**2(0, 2)</p><p>
<sup>&#x02020;&#x02020;</sup>4(2, 2)</p><p>
<sup>&#x02021;&#x02021;</sup>9(3, 6)</p><p>
<sup>&#x000a7;&#x000a7;</sup>10 (4, 6)</p><p>
<sup>||||</sup>12(5, 7)</p><p>
<sup>##</sup>3(1, 2).</p></fn></table-wrap-foot></table-wrap><p>Postoperatively, 7/63 patients required chest reopening (5/33 in LFV versus 2/30 in UC group). Nine patients in the LFV and 6 in the UC groups required intraoperative blood transfusion. Also, 11 participants in the LFV group and 15 in the UC group received blood transfusion (Table&#x000a0;<xref rid="jah310122-supitem-0001" ref-type="supplementary-material">S3</xref>). Postoperative intubation time was 1&#x02009;hour shorter in the LFV group (6.75 [4.25&#x02013;9.75] versus 7.50 [4.25&#x02013;12.63]; Table&#x000a0;<xref rid="jah310122-supitem-0001" ref-type="supplementary-material">S3</xref>).</p><sec id="jah310122-sec-0025"><title>Primary Biochemical Outcomes</title><p>Primary biochemical outcomes are shown in Figure&#x000a0;<xref rid="jah310122-fig-0002" ref-type="fig">2</xref>, Table&#x000a0;<xref rid="jah310122-supitem-0001" ref-type="supplementary-material">S4</xref>, and Figures&#x000a0;<xref rid="jah310122-supitem-0001" ref-type="supplementary-material">S1</xref> and <xref rid="jah310122-supitem-0001" ref-type="supplementary-material">S2</xref>.</p><fig position="float" fig-type="Figure" id="jah310122-fig-0002"><label>Figure 2</label><caption><title>Effect of LFV on primary biomarkers outcome.</title><p>Forest plot illustrating the treatment effect for each biomarker. All the biomarkers shown, with the exception of S1P, were reported in pg/mL. The mean difference for tPAI&#x02010;1 was MD=81.5, 95% CI (&#x02212;431.8 to 594.8) and is not presented in the figure. S1P was reported in &#x003bc;g/L. CPB indicates cardiopulmonary bypass; GMR, geometric mean ratio; IL, interleukin; LFV, low frequency ventilation; MD, mean difference; TNF&#x003b1;, tumor necrosis factor alpha; tPAI&#x02010;1, plasminogen activator inhibitor&#x02010;1; S1P, sphingosine&#x02010;1&#x02010;phosphate; sICAM&#x02010;1, soluble intercellular adhesion molecules&#x02010;1; sRAGE, soluble receptor for advance glycation end products; and sVCAM&#x02010;1, soluble vascular cell adhesion molecules&#x02010;1.</p></caption><graphic xlink:href="JAH3-13-e035011-g002" position="anchor" id="jats-graphic-3"/></fig><p>None of the generic biomarkers tested showed a difference overtime between groups (Figure&#x000a0;<xref rid="jah310122-fig-0002" ref-type="fig">2</xref>, Figures&#x000a0;<xref rid="jah310122-supitem-0001" ref-type="supplementary-material">S1</xref> and <xref rid="jah310122-supitem-0001" ref-type="supplementary-material">S2</xref> and Table&#x000a0;<xref rid="jah310122-supitem-0001" ref-type="supplementary-material">S4</xref>). With regard to sRAGE, the only lung&#x02010;specific biomarker used, the circulating levels were 3 times higher in the LFV group compared with the UC group at 10&#x02009;minutes post CPB weaning (geometric mean ratio, 3.05 [95% CI, 1.13&#x02013;8.24], <italic toggle="yes">P</italic>=0.026). Thereafter, the difference between groups gradually changed over to become significantly higher in the UC group at 24&#x02009;hours post CPB weaning (geometric mean ratio, 0.62 [95% CI, 0.45&#x02013;0.85], <italic toggle="yes">P</italic>=0.003) (Figure&#x000a0;<xref rid="jah310122-fig-0002" ref-type="fig">2</xref>, Figure&#x000a0;<xref rid="jah310122-supitem-0001" ref-type="supplementary-material">S2</xref>, and Table&#x000a0;<xref rid="jah310122-supitem-0001" ref-type="supplementary-material">S4</xref>). TXA2 and IL&#x02010;6 were not detectable despite following strictly the manufacturer's instructions, hence they are not shown. All the other biomarkers measured are reported in pg/mL, with the exception of sphingosine 1&#x02010;phosphate, which is reported in &#x003bc;g/L.</p></sec><sec id="jah310122-sec-0026"><title>Secondary Functional Outcomes</title><p>Secondary functional outcomes are shown in Table&#x000a0;<xref rid="jah310122-tbl-0003" ref-type="table">3</xref> and Figure&#x000a0;<xref rid="jah310122-supitem-0001" ref-type="supplementary-material">S3</xref>. At baseline, FVC, FEV1, and FEV1/FVC ratio were balanced between groups. Postoperatively, the FVC was 0.19&#x02009;L higher (95% CI, &#x02212;0.012 to 0.394; <italic toggle="yes">P</italic>=0.05) and the FEV1 was 0.135&#x02009;L higher (95% CI, &#x02212;0.019 to 0.290; <italic toggle="yes">P</italic>=0.08) in the LFV group versus UC group. Before hospital discharge the FEV1/FVC ratio was similar in the 2 groups, but this was 5% (95% CI, 0.7% to 9.3%) higher in the LFV group at 6 to 8&#x02009;weeks post discharge (<italic toggle="yes">P</italic>=0.02). Alveolar&#x02010;arterial oxygenation rose similarly from baseline in both groups (mean difference, 6.76 [95% CI, &#x02212;25.2 to 38.7]) with no differences between groups. The respiratory index was better in the LFV group 10&#x02009;minutes after CPB weaning (mean difference, &#x02212;0.61 [95% CI, &#x02212;1.24 to 0.0015], <italic toggle="yes">P</italic>=0.05) and overall (<italic toggle="yes">P</italic>=0.05). Peak airway pressure and left atrial/right atrial white blood cell ratio were similar between groups (Table&#x000a0;<xref rid="jah310122-tbl-0003" ref-type="table">3</xref>). The 6MWT score at predischarge showed that the patients in the LFV group walked on average 63.2&#x02009;m more (95% CI, 12.9&#x02009;m&#x02013;113.6&#x02009;m) than those recruited in the UC group (<italic toggle="yes">P</italic>=0.012) (Table&#x000a0;<xref rid="jah310122-supitem-0001" ref-type="supplementary-material">S5</xref>).</p></sec></sec><sec id="jah310122-sec-0027"><title>Clinical and Safety Outcome</title><p>Postoperative clinical complications are reported only descriptively as the trial was not powered for these measures. These occurred overall in 9/63 patients, of whom 5/33 were in the LFV group and 4/30 in the UC group (relative risk, 1.24 [95% CI, 0.39&#x02013;3.91]). Lung complications, time fit for discharge, and adverse events postsurgery up to 6 to 8&#x02009;weeks post discharge are reported in Tables&#x000a0;<xref rid="jah310122-supitem-0001" ref-type="supplementary-material">S5</xref> through <xref rid="jah310122-supitem-0001" ref-type="supplementary-material">S7</xref>. There were no postoperative deaths, myocardial infarctions, permanent strokes, or cases of renal failure requiring dialysis. No differences were observed for serious adverse events, intensive care length of stay, or hospital length of stay.</p></sec></sec><sec sec-type="discussion" id="jah310122-sec-0028"><title>Discussion</title><p>This phase II trial suggests that the use of LFV during CPB is feasible and safe in patients undergoing MV or aortic valve surgery. In addition, it suggests that the use of LFV is associated with marked postoperative changes of sRAGE levels along with better preservation of few pulmonary function tests (respiratory index at 10&#x02009;minutes after CPB weaning and overall, FVC and FEV1/FVC ratio at 6&#x02013;8&#x02009;weeks post discharge) and longer 6&#x02009;minutes walking performance at predischarge.</p><p>The use of sRAGE was approved by the Trial Steering Committee on completion of patient recruitment and of the pilot laboratory validation at bench assay, which strictly followed manufacturer's instructions for all biomarkers. The rationale for measuring sRAGE was to have a lung&#x02010;specific biomarker of lung injury/preservation, already well known in respiratory medicine,<xref rid="jah310122-bib-0022" ref-type="bibr">
<sup>22</sup>
</xref>, <xref rid="jah310122-bib-0023" ref-type="bibr">
<sup>23</sup>
</xref>, <xref rid="jah310122-bib-0024" ref-type="bibr">
<sup>24</sup>
</xref>, <xref rid="jah310122-bib-0025" ref-type="bibr">
<sup>25</sup>
</xref>, <xref rid="jah310122-bib-0026" ref-type="bibr">
<sup>26</sup>
</xref>, <xref rid="jah310122-bib-0027" ref-type="bibr">
<sup>27</sup>
</xref> over and above the generic biomarkers. Although it is difficult at this stage to speculate if and how the marked changes in sRAGE levels might have influenced the observed changes in pulmonary function tests of this study due to lack of mechanistic data, in respiratory medicine it has been suggested that sRAGE may act as mediator of protective responses to cell injury triggered by oxidative stress and hypoxia<xref rid="jah310122-bib-0023" ref-type="bibr">
<sup>23</sup>
</xref> by binding advanced glycation end&#x02010;products in the extracellular fluid, hence preventing their binding with RAGE.<xref rid="jah310122-bib-0027" ref-type="bibr">
<sup>27</sup>
</xref>, <xref rid="jah310122-bib-0034" ref-type="bibr">
<sup>34</sup>
</xref> High circulating levels of sRAGE have been associated with acute lung conditions such as acute respiratory distress syndrome and trauma,<xref rid="jah310122-bib-0022" ref-type="bibr">
<sup>22</sup>
</xref>, <xref rid="jah310122-bib-0023" ref-type="bibr">
<sup>23</sup>
</xref>, <xref rid="jah310122-bib-0024" ref-type="bibr">
<sup>24</sup>
</xref> as well as with lung injury triggered by high tidal volumes during mechanical ventilation.<xref rid="jah310122-bib-0022" ref-type="bibr">
<sup>22</sup>
</xref> At the same time, low levels of sRAGE have been linked with nonacute lung disease such as idiopathic pulmonary fibrosis,<xref rid="jah310122-bib-0025" ref-type="bibr">
<sup>25</sup>
</xref> acquired lung fibrosis,<xref rid="jah310122-bib-0026" ref-type="bibr">
<sup>26</sup>
</xref> and chronic obstructive lung disease,<xref rid="jah310122-bib-0027" ref-type="bibr">
<sup>27</sup>
</xref> with speculations that higher sRAGE levels in these patients might be beneficial.</p><p>The PROVECS (Protective Ventilation in Cardiac Surgery) trial tested, in a mixed group of 500 patients undergoing cardiac surgery, a complex open&#x02010;lung method involving high PEEP (8&#x02009;cmH<sub>2</sub>O) and lung recruitment maneuvers with continuous positive airway pressure at 30&#x02009;cmH<sub>2</sub>O for 30&#x02009;seconds repeated 5 times during surgery and up to extubation time; the control group involved only low PEEP (2&#x02009;cmH<sub>2</sub>O), no ventilation during CPB, and no recruitment maneuvers.<xref rid="jah310122-bib-0017" ref-type="bibr">
<sup>17</sup>
</xref> The PROVECS trial showed no differences of primary composite of postoperative pulmonary complications. In addition, 2 later subanalyses of this trial in 56 and 30 patients showed no effects on postoperative lung function and sRAGE levels respectively, the latter representing the only cardiac surgery study reporting perioperative sRAGE levels so far.<xref rid="jah310122-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref> The major differences in open&#x02010;lung methods and targeted patient population occurred between PROVECS and the present study might explain the different results observed with regard to sRAGE release and pulmonary function tests, but this speculation requires further validation.</p><p>Pulmonary function tests and 6MWT are used extensively in respiratory medicine for diagnostic or therapeutic decision&#x02010;making.<xref rid="jah310122-bib-0022" ref-type="bibr">
<sup>22</sup>
</xref>, <xref rid="jah310122-bib-0023" ref-type="bibr">
<sup>23</sup>
</xref>, <xref rid="jah310122-bib-0024" ref-type="bibr">
<sup>24</sup>
</xref>, <xref rid="jah310122-bib-0025" ref-type="bibr">
<sup>25</sup>
</xref>, <xref rid="jah310122-bib-0026" ref-type="bibr">
<sup>26</sup>
</xref>, <xref rid="jah310122-bib-0027" ref-type="bibr">
<sup>27</sup>
</xref>, <xref rid="jah310122-bib-0033" ref-type="bibr">
<sup>33</sup>
</xref>, <xref rid="jah310122-bib-0034" ref-type="bibr">
<sup>34</sup>
</xref>, <xref rid="jah310122-bib-0035" ref-type="bibr">
<sup>35</sup>
</xref> They are also used in cardiac surgery for preoperative risk profiling of patients to support informed consenting, as their very high sensitivity helps establish levels of preoperative lung injury/dysfunction, ascertaining fitness for surgery and guiding postoperative care. In this study, serial pulmonary tests and 6MWT were undertaken by staff blinded to the allocation. Lung function tests were used first to assess the severity of preoperative pulmonary dysfunction with a view to balancing the distribution of those cases with marked lung dysfunction among groups to avoid confounding. In addition, they were used postoperatively to assess the safety of LVF during valvular surgery as well as the possible benefits of LFV on pulmonary function. The findings of these well&#x02010;established pulmonary tests not only confirm the safety of the proposed LFV method but also suggest that LFV may be associated with better postoperative preservation of the respiratory index, FEV<sub>1</sub>/FVC ratio, and FVC alone, along also with a trend for better FEV<sub>1</sub> alone (Table&#x000a0;<xref rid="jah310122-tbl-0003" ref-type="table">3</xref>). These results appear to be in keeping with a better 6MWT performance in the LVF group at predischarge.</p><p>It might be argued that the findings of this study may conflict with those of other studies assessing the safety/efficacy of open&#x02010;lung methods in patients undergoing cardiac surgery. However, such a comparison may not be meaningful as there are marked differences in open&#x02010;lung methods, targeted patient populations and outcome measures used across these different studies. For example, the PROVECS trial<xref rid="jah310122-bib-0017" ref-type="bibr">
<sup>17</sup>
</xref>, <xref rid="jah310122-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref> not only tested a more complex open&#x02010;lung method but also recruited a very mixed population (28% of CABG only, 25% of thoracic aorta or combined procedures, and 47% of valve only patients) with no balancing for severe preoperative lung dysfunction across groups. In the present phase II trial the LFV method used was simple and applied only during CPB (all other aspects of care were similar between groups), whereas among all patients who underwent valvular surgery 9/63 cases received bypass grafts on top of valvular surgery, which were equally distributed between groups (Table&#x000a0;<xref rid="jah310122-tbl-0001" ref-type="table">1</xref>). Another trial in 1500 patients who received cardiac surgery tested a simple open&#x02010;lung method only during CPB (5&#x02009;breath/min; 3&#x02009;mL/kg of tidal volume and PEEP of 5&#x02009;cmH<sub>2</sub>O), reporting no difference between groups.<xref rid="jah310122-bib-0019" ref-type="bibr">
<sup>19</sup>
</xref> Again, the targeted population was quite mixed (&#x0003e;50% of CABG alone cases along with acute endocarditis and redo cardiac surgery cases). Surprisingly, 172/756 patients recruited in the open&#x02010;lung group did not receive the intended treatment and this represented a major methodological weakness. A further trial recruited 413 patients who received cardiac surgery across 3 groups (no open&#x02010;lung method, open&#x02010;lung at low tidal volume, or open&#x02010;lung at high tidal volume during CPB), reporting better oxygenation index in the open&#x02010;lung groups versus control, but no effect on the primary composite of postoperative complications.<xref rid="jah310122-bib-0020" ref-type="bibr">
<sup>20</sup>
</xref> Finally, a meta&#x02010;analysis pooled 15 small trials (738 patients in total) despite the trials using very different open&#x02010;lung methods and 13/15 of the trials recruiting patients undergoing CABG alone.<xref rid="jah310122-bib-0021" ref-type="bibr">
<sup>21</sup>
</xref> The study reported no benefits associated with the pooled open&#x02010;lung methods.</p><p>This study has limitations. Despite randomization and blinding, minor heterogeneities occurred by chance in distribution of some baseline factors, with trends toward less MV disease and diabetes in the usual care group and a slightly lower EuroSCORE in the LFV group. In addition, the outcome measures focused on biochemical and pulmonary function tests given their high sensitivity as this was a phase II small trial. We appreciate that focusing on rare and more robust clinical outcomes would have required a much larger phase III trial. It might be argued that LFV is not justified as this trial did not show differences for the other generic biomarkers and clinical outcomes tested. However, expecting LFV to affect generic biomarkers such as inflammatory markers may not be realistic given that in both groups patients required prolonged CPB and cardioplegic arrest times that are well&#x02010;known determinants of postoperative inflammatory activation. Equally, expecting benefits in clinical outcome triggered by LFV may also not be realistic as this was a phase II trial not powered for clinical end points. Also, it could be argued that a subanalysis might have clarified whether the impact of LVF might have been different on patients with aortic valve disease versus those with mitral valve disease given their possible different effects on pulmonary circulation. However, we did not undertake this subanalysis due to it not being prespecified in our analysis plan and the subgroups being too small to provide meaningful additional information. Finally, there was delay from completion of patient recruitment and follow&#x02010;up to submission of this paper for publication. However, the quality of our findings was not affected as rigorous methodological approaches were used throughout and for each methodological aspect of the study. Finally, the anesthetic and surgical techniques used during the patient recruitment period are similar to those used currently, making the findings of this study still relevant to current practice.</p><sec sec-type="conclusions" id="jah310122-sec-0029"><title>Conclusions</title><p>In conclusion, in this phase II trial the use of LFV during CPB in patients undergoing valvular surgery was feasible and safe. In addition, LFV triggered postoperative changes in sRAGE levels along with better preservation of few lung function tests and 6MWT performance in the postoperative period. Although these observations are interesting, they warrant further investigation in future larger studies with focus on clinical end points.</p></sec></sec><sec id="jah310122-sec-0031"><title>Sources of Funding</title><p>The trial was led by Raimondo Ascione, who also performed most of the surgery. The trial was supported by the National Institute of Health Research Bristol Cardiovascular Biomedical Research Unit. Raimondo Ascione is supported by grants from the National Institute of Health Research, Innovate UK, Medical Research Council, and the British Heart Foundation. This trial was delivered by the Clinical Trial Evaluation Unit, now Bristol Trials Centre, a UK Clinical Research Collaboration registered clinical trials unit that is in receipt of National Institute of Health Research Clinical Trials Unit support funding. The views and opinions expressed in this report are those of the authors and do not necessarily reflect those of the National Institute of Health Research, National Health Service or the Department of Health and Social Care.</p></sec><sec id="jah310122-sec-0032"><title>Disclosures</title><p>None.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="jah310122-supitem-0001" position="float" content-type="local-data"><caption><p>Data S1</p></caption><media xlink:href="JAH3-13-e035011-s001.pdf"/></supplementary-material></sec></body><back><ack id="jah310122-sec-0030"><title>Acknowledgments</title><p>We thank all trial team members involved in PROTECTION and the surgeons agreeing to support this study. We are very grateful to all the patients agreeing to be enrolled in this trial.</p></ack><ref-list content-type="cited-references" id="jah310122-bibl-0001"><title>References</title><ref id="jah310122-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="jah310122-cit-0001">
<string-name>
<surname>Bartz</surname>
<given-names>RR</given-names>
</string-name>, <string-name>
<surname>Ferreira</surname>
<given-names>RG</given-names>
</string-name>, <string-name>
<surname>Schroder</surname>
<given-names>JN</given-names>
</string-name>, <string-name>
<surname>Davies</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Liu</surname>
<given-names>W&#x02010;W</given-names>
</string-name>, <string-name>
<surname>Camara</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Welsby</surname>
<given-names>IJ</given-names>
</string-name>. <article-title>Prolonged pulmonary support after cardiac surgery: incidence, risk factors and outcomes: a retrospective cohort study</article-title>. <source>J Crit Care</source>. <year>2015</year>;<volume>30</volume>:<fpage>940</fpage>&#x02013;<lpage>944</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jcrc.2015.04.125</pub-id>
<pub-id pub-id-type="pmid">26205187</pub-id>
</mixed-citation></ref><ref id="jah310122-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="jah310122-cit-0002">
<string-name>
<surname>Badenes</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Lozano</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Belda</surname>
<given-names>FJ</given-names>
</string-name>. <article-title>Postoperative pulmonary dysfunction and mechanical ventilation in cardiac surgery</article-title>. <source>Crit Care Res Pract</source>. <year>2015</year>;<volume>2015</volume>:<elocation-id>420513</elocation-id>. doi: <pub-id pub-id-type="doi">10.1155/2015/420513</pub-id>
<pub-id pub-id-type="pmid">25705516</pub-id>
</mixed-citation></ref><ref id="jah310122-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="jah310122-cit-0003">
<string-name>
<surname>Rajakaruna</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Rogers</surname>
<given-names>CA</given-names>
</string-name>, <string-name>
<surname>Angelini</surname>
<given-names>GD</given-names>
</string-name>, <string-name>
<surname>Ascione</surname>
<given-names>R</given-names>
</string-name>. <article-title>Risk factors for and economic implications of prolonged ventilation after cardiac surgery</article-title>. <source>J Thorac Cardiovasc Surg</source>. <year>2005</year>;<volume>130</volume>:<fpage>1270</fpage>&#x02013;<lpage>1277</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jtcvs.2005.06.050</pub-id>
<pub-id pub-id-type="pmid">16256778</pub-id>
</mixed-citation></ref><ref id="jah310122-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="jah310122-cit-0004">
<string-name>
<surname>Nteliopoulos</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Nikolakopoulou</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Chow</surname>
<given-names>BHN</given-names>
</string-name>, <string-name>
<surname>Corless</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Nguyen</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Dimarakis</surname>
<given-names>I</given-names>
</string-name>. <article-title>Lung injury following cardiopulmonary bypass: a clinical update</article-title>. <source>Expert Rev Cardiovasc Ther</source>. <year>2022</year>;<volume>20</volume>:<fpage>871</fpage>&#x02013;<lpage>880</lpage>. doi: <pub-id pub-id-type="doi">10.1080/14779072.2022.2149492</pub-id>
<pub-id pub-id-type="pmid">36408601</pub-id>
</mixed-citation></ref><ref id="jah310122-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="jah310122-cit-0005">
<string-name>
<surname>Sanfilippo</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Palumbo</surname>
<given-names>GJ</given-names>
</string-name>, <string-name>
<surname>Bignami</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Pavesi</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Ranucci</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Scolletta</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Pelosi</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Astuto</surname>
<given-names>M</given-names>
</string-name>. <article-title>Acute respiratory distress syndrome in the perioperative period of cardiac surgery: predictors, diagnosis, prognosis, management options, and future directions</article-title>. <source>J Cardiothorac Vasc Anesth</source>. <year>2022</year>;<volume>36</volume>:<fpage>1169</fpage>&#x02013;<lpage>1179</lpage>. doi: <pub-id pub-id-type="doi">10.1053/j.jvca.2021.04.024</pub-id>
<pub-id pub-id-type="pmid">34030957</pub-id>
</mixed-citation></ref><ref id="jah310122-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="jah310122-cit-0006">
<string-name>
<surname>Magnusson</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Zemgulis</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Wicky</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Tyden</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Thelin</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Hedenstierna</surname>
<given-names>G</given-names>
</string-name>. <article-title>Atelectasis is a major cause of hypoxemia and shunt after cardiopulmonary bypass. An experimental study</article-title>. <source>Anesthesiology</source>. <year>1996</year>;<volume>87</volume>:<fpage>1153</fpage>&#x02013;<lpage>1163</lpage>. doi: <pub-id pub-id-type="doi">10.1097/00000542-199711000-00020</pub-id>
</mixed-citation></ref><ref id="jah310122-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="jah310122-cit-0007">
<string-name>
<surname>Young</surname>
<given-names>RW</given-names>
</string-name>. <article-title>Prevention of lung injury in cardiac surgery: a review</article-title>. <source>J Extra Corpor Technol</source>. <year>2014</year>;<volume>46</volume>:<fpage>130</fpage>&#x02013;<lpage>141</lpage>. doi: <pub-id pub-id-type="doi">10.1051/ject/201446130</pub-id>
<pub-id pub-id-type="pmid">25208430</pub-id>
</mixed-citation></ref><ref id="jah310122-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="jah310122-cit-0008">
<string-name>
<surname>Ascione</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Lloyd</surname>
<given-names>CT</given-names>
</string-name>, <string-name>
<surname>Underwood</surname>
<given-names>MJ</given-names>
</string-name>, <string-name>
<surname>Lotto</surname>
<given-names>AA</given-names>
</string-name>, <string-name>
<surname>Pitsis</surname>
<given-names>AA</given-names>
</string-name>, <string-name>
<surname>Angelini</surname>
<given-names>GD</given-names>
</string-name>. <article-title>Inflammatory response after coronary revascularization with or without cardiopulmonary bypass</article-title>. <source>Ann Thorac Surg</source>. <year>2000</year>;<volume>69</volume>:<fpage>1198</fpage>&#x02013;<lpage>1204</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S0003-4975(00)01152-8</pub-id>
<pub-id pub-id-type="pmid">10800819</pub-id>
</mixed-citation></ref><ref id="jah310122-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="jah310122-cit-0009">
<string-name>
<surname>Meier</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Lange</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Papenberg</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Ziemann</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Fentrop</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Uhlig</surname>
<given-names>U</given-names>
</string-name>, <string-name>
<surname>Schmucker</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Uhlig</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Stamme</surname>
<given-names>C</given-names>
</string-name>. <article-title>Pulmonary cytokine responses during mechanical ventilation of non&#x02010;injured lungs with and without end&#x02010;expiratory pressure</article-title>. <source>Anesth Analg</source>. <year>2008</year>;<volume>107</volume>:<fpage>1265</fpage>&#x02013;<lpage>1275</lpage>. doi: <pub-id pub-id-type="doi">10.1213/ane.0b013e3181806212</pub-id>
<pub-id pub-id-type="pmid">18806039</pub-id>
</mixed-citation></ref><ref id="jah310122-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="jah310122-cit-0010">
<string-name>
<surname>Rhodes</surname>
<given-names>KM</given-names>
</string-name>, <string-name>
<surname>Evemy</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Nariman</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Gibson</surname>
<given-names>GJ</given-names>
</string-name>. <article-title>Relation between severity of mitral valve disease and results of routine lung function tests in non&#x02010;smokers</article-title>. <source>Thorax</source>. <year>1982</year>;<volume>37</volume>:<fpage>751</fpage>&#x02013;<lpage>755</lpage>. doi: <pub-id pub-id-type="doi">10.1136/thx.37.10.751</pub-id>
<pub-id pub-id-type="pmid">7157214</pub-id>
</mixed-citation></ref><ref id="jah310122-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="jah310122-cit-0011">
<string-name>
<surname>McVey</surname>
<given-names>MJ</given-names>
</string-name>, <string-name>
<surname>Kapur</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Cserti&#x02010;Gazdewich</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Semple</surname>
<given-names>JW</given-names>
</string-name>, <string-name>
<surname>Karkouti</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Kuebler</surname>
<given-names>WM</given-names>
</string-name>. <article-title>Transfusion&#x02010;related acute lung injury in the perioperative patient</article-title>. <source>Anesthesiology</source>. <year>2019</year>;<volume>131</volume>:<fpage>693</fpage>&#x02013;<lpage>715</lpage>. doi: <pub-id pub-id-type="doi">10.1097/ALN.0000000000002687</pub-id>
<pub-id pub-id-type="pmid">31408449</pub-id>
</mixed-citation></ref><ref id="jah310122-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="jah310122-cit-0012">
<string-name>
<surname>Murphy</surname>
<given-names>GJ</given-names>
</string-name>, <string-name>
<surname>Reeves</surname>
<given-names>BC</given-names>
</string-name>, <string-name>
<surname>Rogers</surname>
<given-names>CA</given-names>
</string-name>, <string-name>
<surname>Rizvi</surname>
<given-names>SIA</given-names>
</string-name>, <string-name>
<surname>Culliford</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Angelini</surname>
<given-names>D</given-names>
</string-name>. <article-title>Increased mortality, postoperative morbidity, and cost after red blood cell transfusion in patients having cardiac surgery</article-title>. <source>Circulation</source>. <year>2007</year>;<volume>116</volume>:<fpage>2544</fpage>&#x02013;<lpage>2552</lpage>. doi: <pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.107.698977</pub-id>
<pub-id pub-id-type="pmid">17998460</pub-id>
</mixed-citation></ref><ref id="jah310122-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="jah310122-cit-0013">
<string-name>
<surname>Miranda</surname>
<given-names>DR</given-names>
</string-name>, <string-name>
<surname>Gommers</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Struijs</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Dekker</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Mekel</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Feelders</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Lachmann</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Bogers</surname>
<given-names>AJJC</given-names>
</string-name>. <article-title>Ventilation according to the open lung concept attenuates pulmonary inflammatory response in cardiac surgery</article-title>. <source>Eur J Cardiothorac Surg</source>. <year>2005</year>;<volume>28</volume>:<fpage>889</fpage>&#x02013;<lpage>895</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.ejcts.2005.10.007</pub-id>
<pub-id pub-id-type="pmid">16271479</pub-id>
</mixed-citation></ref><ref id="jah310122-bib-0014"><label>14</label><mixed-citation publication-type="book" id="jah310122-cit-0014">
<string-name>
<surname>Imura</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Ascione</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Angelini</surname>
<given-names>GD</given-names>
</string-name>. <source>Principles of Pulmonary Protection in Heart Surgery</source>. <publisher-loc>Berlin</publisher-loc>: <publisher-name>Springer Science &#x00026; Business Media</publisher-name>; <year>2010</year>. doi: <pub-id pub-id-type="doi">10.1007/978-1-84996-308-4_39</pub-id>
</mixed-citation></ref><ref id="jah310122-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="jah310122-cit-0015">
<string-name>
<surname>Imura</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Angelini</surname>
<given-names>GD</given-names>
</string-name>, <string-name>
<surname>Suleiman</surname>
<given-names>MS</given-names>
</string-name>, <string-name>
<surname>Ascione</surname>
<given-names>R</given-names>
</string-name>. <article-title>Lung ventilation/perfusion may reduce pulmonary injury during cardiopulmonary bypass</article-title>. <source>JTCVS</source>. <year>2010</year>;<volume>139</volume>:<fpage>236</fpage>&#x02013;<lpage>237</lpage>.</mixed-citation></ref><ref id="jah310122-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="jah310122-cit-0016">
<string-name>
<surname>Fiorentino</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Al&#x02010;Jaaly</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Durham</surname>
<given-names>AL</given-names>
</string-name>, <string-name>
<surname>Adcock</surname>
<given-names>IM</given-names>
</string-name>, <string-name>
<surname>Lockwood</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Rogers</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Ascione</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Reeves</surname>
<given-names>BC</given-names>
</string-name>, <string-name>
<surname>Angelini</surname>
<given-names>GD</given-names>
</string-name>. <article-title>Low&#x02010;frequency ventilation during cardiopulmonary bypass for lung protection: a randomized controlled trial</article-title>. <source>J Card Surg</source>. <year>2019</year>;<volume>34</volume>:<fpage>385</fpage>&#x02013;<lpage>399</lpage>. doi: <pub-id pub-id-type="doi">10.1111/jocs.14044</pub-id>
<pub-id pub-id-type="pmid">31045289</pub-id>
</mixed-citation></ref><ref id="jah310122-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="jah310122-cit-0017">
<string-name>
<surname>Lagier</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Fischer</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Fornier</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Huynh</surname>
<given-names>TM</given-names>
</string-name>, <string-name>
<surname>Cholley</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Guinard</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Heger</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Quintana</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Villacorta</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Gaillat</surname>
<given-names>F</given-names>
</string-name>, et&#x000a0;al. <article-title>Effect of open&#x02010;lung vs conventional perioperative ventilation strategies on postoperative pulmonary complications after on&#x02010;pump cardiac surgery: the PROVECS randomized clinical trial</article-title>. <source>Intensive Care Med</source>. <year>2019</year>;<volume>45</volume>:<fpage>1401</fpage>&#x02013;<lpage>1412</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s00134-019-05741-8</pub-id>
<pub-id pub-id-type="pmid">31576435</pub-id>
</mixed-citation></ref><ref id="jah310122-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="jah310122-cit-0018">
<string-name>
<surname>Lagier</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Velly</surname>
<given-names>LJ</given-names>
</string-name>, <string-name>
<surname>Guinard</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Bruder</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Guidon</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Melo</surname>
<given-names>MFV</given-names>
</string-name>, <string-name>
<surname>Alessi</surname>
<given-names>MC</given-names>
</string-name>. <article-title>Perioperative open&#x02010;lung approach, regional ventilation, and lung injury in cardiac surgery: a PROVECS trial substudy</article-title>. <source>Anesthesiology</source>. <year>2020</year>;<volume>133</volume>:<fpage>1029</fpage>&#x02013;<lpage>1045</lpage>. doi: <pub-id pub-id-type="doi">10.1097/ALN.0000000000003539</pub-id>
<pub-id pub-id-type="pmid">32902561</pub-id>
</mixed-citation></ref><ref id="jah310122-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="jah310122-cit-0019">
<string-name>
<surname>Nguyen</surname>
<given-names>LS</given-names>
</string-name>, <string-name>
<surname>Estagnasie</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Merzoug</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Brusset</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Law Koune</surname>
<given-names>JD</given-names>
</string-name>, <string-name>
<surname>Aubert</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Waldmann</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Naudin</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Grinda</surname>
<given-names>JM</given-names>
</string-name>, <string-name>
<surname>Gibert</surname>
<given-names>H</given-names>
</string-name>, et&#x000a0;al. <article-title>Low tidal volume mechanical ventilation against no ventilation during cardiopulmonary bypass in heart surgery (MECANO): a randomized controlled trial</article-title>. <source>Chest</source>. <year>2021</year>;<volume>159</volume>:<fpage>1843</fpage>&#x02013;<lpage>1853</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.chest.2020.10.082</pub-id>
<pub-id pub-id-type="pmid">33217416</pub-id>
</mixed-citation></ref><ref id="jah310122-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="jah310122-cit-0020">
<string-name>
<surname>Zhang</surname>
<given-names>MQ</given-names>
</string-name>, <string-name>
<surname>Liao</surname>
<given-names>YQ</given-names>
</string-name>, <string-name>
<surname>Yu</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>XF</given-names>
</string-name>, <string-name>
<surname>Shi</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Jing</surname>
<given-names>WW</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>ZL</given-names>
</string-name>, <string-name>
<surname>Xu</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Yu</surname>
<given-names>H</given-names>
</string-name>. <article-title>Effect of ventilation strategy during cardiopulmonary bypass on postoperative pulmonary complications after cardiac surgery: a randomized clinical trial</article-title>. <source>J Cardiothorac Surg</source>. <year>2021</year>;<volume>16</volume>:<fpage>319</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s13019-021-01699-1</pub-id>
<pub-id pub-id-type="pmid">34717700</pub-id>
</mixed-citation></ref><ref id="jah310122-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="jah310122-cit-0021">
<string-name>
<surname>Wang</surname>
<given-names>YC</given-names>
</string-name>, <string-name>
<surname>Huang</surname>
<given-names>CH</given-names>
</string-name>, <string-name>
<surname>Tu</surname>
<given-names>YK</given-names>
</string-name>. <article-title>Effects of positive airway pressure and mechanical ventilation of the lungs during cardiopulmonary bypass on pulmonary adverse events after cardiac surgery: a systematic review and meta&#x02010;analysis</article-title>. <source>J Cardiothorac Vasc Anesth</source>. <year>2018</year>;<volume>32</volume>:<fpage>748</fpage>&#x02013;<lpage>759</lpage>. doi: <pub-id pub-id-type="doi">10.1053/j.jvca.2017.09.013</pub-id>
<pub-id pub-id-type="pmid">29229259</pub-id>
</mixed-citation></ref><ref id="jah310122-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="jah310122-cit-0022">
<string-name>
<surname>Calfee</surname>
<given-names>CS</given-names>
</string-name>, <string-name>
<surname>Ware</surname>
<given-names>LB</given-names>
</string-name>, <string-name>
<surname>Eisner</surname>
<given-names>MD</given-names>
</string-name>, <string-name>
<surname>Parsons</surname>
<given-names>PE</given-names>
</string-name>, <string-name>
<surname>Thompson</surname>
<given-names>BT</given-names>
</string-name>, <string-name>
<surname>Wickersham</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Matthay</surname>
<given-names>MA</given-names>
</string-name>; <collab collab-type="authors">NHLBI ARDS Network</collab>
. <article-title>Plasma receptor for advanced glycation end products and clinical outcomes in acute lung injury</article-title>. <source>Thorax</source>. <year>2008</year>;<volume>63</volume>:<fpage>1083</fpage>&#x02013;<lpage>1089</lpage>. doi: <pub-id pub-id-type="doi">10.1136/thx.2008.095588</pub-id>
<pub-id pub-id-type="pmid">18566109</pub-id>
</mixed-citation></ref><ref id="jah310122-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="jah310122-cit-0023">
<string-name>
<surname>Jabaudon</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Blondonnet</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Pereira</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Cartin&#x02010;Ceba</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Lichtenstern</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Mauri</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Determann</surname>
<given-names>RM</given-names>
</string-name>, <string-name>
<surname>Drabek</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Hubmayr</surname>
<given-names>RD</given-names>
</string-name>, <string-name>
<surname>Gajic</surname>
<given-names>O</given-names>
</string-name>, et&#x000a0;al. <article-title>Plasma sRAGE is independently associated with increased mortality in ARDS: a meta&#x02010;analysis of individual patient data</article-title>. <source>Intensive Care Med</source>. <year>2018</year>;<volume>44</volume>:<fpage>1388</fpage>&#x02013;<lpage>1399</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s00134-018-5327-1</pub-id>
<pub-id pub-id-type="pmid">30051136</pub-id>
</mixed-citation></ref><ref id="jah310122-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="jah310122-cit-0024">
<string-name>
<surname>Lim</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Radujkovic</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Weigand</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Merle</surname>
<given-names>U</given-names>
</string-name>. <article-title>Soluble receptor for advanced glycation end products (sRAGE) as a biomarker of COVID&#x02010;19 disease severity and indicator of the need for mechanical ventilation, ARDS and mortality</article-title>. <source>Ann Intensive Care</source>. <year>2021</year>;<volume>22</volume>:<fpage>50</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s13613-021-00836-2</pub-id>
</mixed-citation></ref><ref id="jah310122-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="jah310122-cit-0025">
<string-name>
<surname>Manichaikul</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Sun</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Borczuk</surname>
<given-names>AC</given-names>
</string-name>, <string-name>
<surname>Onengut&#x02010;Gumuscu</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Farber</surname>
<given-names>EA</given-names>
</string-name>, <string-name>
<surname>Mathai</surname>
<given-names>SK</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Raghu</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Kaufman</surname>
<given-names>JD</given-names>
</string-name>, <string-name>
<surname>Hinckley&#x02010;Stukovsky</surname>
<given-names>KD</given-names>
</string-name>, et&#x000a0;al. <article-title>Plasma soluble receptor for advanced glycation end products in idiopathic pulmonary fibrosis</article-title>. <source>Ann Am Thorac Soc</source>. <year>2017</year>;<volume>14</volume>:<fpage>628</fpage>&#x02013;<lpage>635</lpage>. doi: <pub-id pub-id-type="doi">10.1513/AnnalsATS.201606-485OC</pub-id>
<pub-id pub-id-type="pmid">28248552</pub-id>
</mixed-citation></ref><ref id="jah310122-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="jah310122-cit-0026">
<string-name>
<surname>Queisser</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Kouri</surname>
<given-names>FM</given-names>
</string-name>, <string-name>
<surname>Konigshoff</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Wygrecka</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Schubert</surname>
<given-names>U</given-names>
</string-name>, <string-name>
<surname>Eickelberg</surname>
<given-names>O</given-names>
</string-name>, <string-name>
<surname>Preissner</surname>
<given-names>KT</given-names>
</string-name>. <article-title>Loss of RAGE in pulmonary fibrosis: molecular relations to functional changes in pulmonary cell types</article-title>. <source>Am J Respir Cell Mol Biol</source>. <year>2008</year>;<volume>39</volume>:<fpage>337</fpage>&#x02013;<lpage>345</lpage>. doi: <pub-id pub-id-type="doi">10.1165/rcmb.2007-0244OC</pub-id>
<pub-id pub-id-type="pmid">18421017</pub-id>
</mixed-citation></ref><ref id="jah310122-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="jah310122-cit-0027">
<string-name>
<surname>Smith</surname>
<given-names>DJ</given-names>
</string-name>, <string-name>
<surname>Yerkovich</surname>
<given-names>ST</given-names>
</string-name>, <string-name>
<surname>Towers</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Carroll</surname>
<given-names>ML</given-names>
</string-name>, <string-name>
<surname>Thomas</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Upham</surname>
<given-names>JW</given-names>
</string-name>. <article-title>Reduced soluble receptor for advanced glycation end&#x02010;products in COPD</article-title>. <source>Eur Respir J</source>. <year>2011</year>;<volume>37</volume>:<fpage>516</fpage>&#x02013;<lpage>522</lpage>. doi: <pub-id pub-id-type="doi">10.1183/09031936.00029310</pub-id>
<pub-id pub-id-type="pmid">20595148</pub-id>
</mixed-citation></ref><ref id="jah310122-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="jah310122-cit-0028">
<string-name>
<surname>Sarkar</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Harris</surname>
<given-names>RA</given-names>
</string-name>, <string-name>
<surname>Wells</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Harris</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Clout</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Taylor</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Culliford</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Angelini</surname>
<given-names>GD</given-names>
</string-name>, <string-name>
<surname>Pike</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Ashton</surname>
<given-names>K</given-names>
</string-name>, et&#x000a0;al. <article-title>Preoperative volume replacement therapy in diabetic patients undergoing coronary artery bypass grafting surgery: results from an open parallel group randomized controlled trial (VERDICT)</article-title>. <source>Interact Cardiovasc Thorac Surg</source>. <year>2019</year>;<volume>30</volume>:<fpage>54</fpage>&#x02013;<lpage>63</lpage>. doi: <pub-id pub-id-type="doi">10.1093/icvts/ivz226</pub-id>
</mixed-citation></ref><ref id="jah310122-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="jah310122-cit-0029">
<string-name>
<surname>Bhargava</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Wendt</surname>
<given-names>CH</given-names>
</string-name>. <article-title>Biomarkers in acute lung injury</article-title>. <source>Transl Res</source>. <year>2012</year>;<volume>159</volume>:<fpage>205</fpage>&#x02013;<lpage>217</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.trsl.2012.01.007</pub-id>
<pub-id pub-id-type="pmid">22424425</pub-id>
</mixed-citation></ref><ref id="jah310122-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="jah310122-cit-0030">
<string-name>
<surname>Chung</surname>
<given-names>MY</given-names>
</string-name>, <string-name>
<surname>Park</surname>
<given-names>SY</given-names>
</string-name>, <string-name>
<surname>Chung</surname>
<given-names>JO</given-names>
</string-name>, <string-name>
<surname>Cho</surname>
<given-names>DH</given-names>
</string-name>, <string-name>
<surname>Chung</surname>
<given-names>DJ</given-names>
</string-name>. <article-title>Plasma sphingosine 1&#x02010;phosphate concentrations and cardiovascular autonomic neuropathy in individuals with type 2 diabetes</article-title>. <source>Sci Rep</source>. <year>2020</year>;<volume>10</volume>:<fpage>12768</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41598-020-69566-y</pub-id>
<pub-id pub-id-type="pmid">32728147</pub-id>
</mixed-citation></ref><ref id="jah310122-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="jah310122-cit-0031">
<string-name>
<surname>St&#x000f6;rmann</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Lustenberger</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Relja</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Marzi</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Wutzler</surname>
<given-names>S</given-names>
</string-name>. <article-title>Role of biomarkers in acute traumatic lung injury</article-title>. <source>Injury</source>. <year>2017</year>;<volume>48</volume>:<fpage>2400</fpage>&#x02013;<lpage>2406</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.injury.2017.08.041</pub-id>
<pub-id pub-id-type="pmid">28888717</pub-id>
</mixed-citation></ref><ref id="jah310122-bib-0032"><label>32</label><mixed-citation publication-type="journal" id="jah310122-cit-0032">
<string-name>
<surname>Zhang</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Di</surname>
<given-names>YP</given-names>
</string-name>. <article-title>Fast and efficient measurement of clinical and biological samples using immunoassay&#x02010;based multiplexing systems</article-title>. <source>Methods Mol Biol</source>. <year>2020</year>;<volume>2102</volume>:<fpage>129</fpage>&#x02013;<lpage>147</lpage>. doi: <pub-id pub-id-type="doi">10.1007/978-1-0716-0223-2_6</pub-id>
<pub-id pub-id-type="pmid">31989552</pub-id>
</mixed-citation></ref><ref id="jah310122-bib-0033"><label>33</label><mixed-citation publication-type="book" id="jah310122-cit-0033">
<string-name>
<surname>Matos Casano</surname>
<given-names>HA</given-names>
</string-name>, <string-name>
<surname>Anjum</surname>
<given-names>F</given-names>
</string-name>. <part-title>Six&#x02010;minute walk test</part-title>. <source>StatPearls</source>. <publisher-loc>Treasure Island (FL)</publisher-loc>: <publisher-name>StatPearls Publishing</publisher-name>; <year>2024</year>. <ext-link xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK576420/" ext-link-type="uri">https://www.ncbi.nlm.nih.gov/books/NBK576420/</ext-link>
</mixed-citation></ref><ref id="jah310122-bib-0034"><label>34</label><mixed-citation publication-type="journal" id="jah310122-cit-0034">
<string-name>
<surname>Agarwala</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Salzman</surname>
<given-names>SH</given-names>
</string-name>. <article-title>Six&#x02010;minute walk test: clinical role, technique, coding, and reimbursement</article-title>. <source>Chest</source>. <year>2020</year>;<volume>157</volume>:<fpage>603</fpage>&#x02013;<lpage>611</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.chest.2019.10.014</pub-id>
<pub-id pub-id-type="pmid">31689414</pub-id>
</mixed-citation></ref><ref id="jah310122-bib-0035"><label>35</label><mixed-citation publication-type="journal" id="jah310122-cit-0035">
<string-name>
<surname>Ranu</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Wilde</surname>
<given-names>M</given-names>
</string-name>. <article-title>Pulmonary function tests</article-title>. <source>Ulster Med J</source>. <year>2011</year>;<volume>80</volume>:<fpage>84</fpage>&#x02013;<lpage>90</lpage>.<pub-id pub-id-type="pmid">22347750</pub-id>
</mixed-citation></ref></ref-list></back></article>